The local organising committee this year was headed by Associate Professor Samuel Zagarella as Convenor, Dr Ian Hamann and Dr Monisha Gupta as Co-Convenors, and supported by the College’s Scientific Meetings Steering Committee. The New South Wales Faculty welcomes Fellows, trainees, students and other medical practitioners to the meeting.

I am excited to welcome our overseas speakers:

- **Professor Alex Anstey**, Honorary Professor of Dermatology at Cardiff University, Advisory Professor of Dermatology to Jiao Tong University, Shanghai, China and Editor of the *British Journal of Dermatology* (BJD), Bangor, North Wales.
- **Dr Ashfaq Marghoob**, Director, Memorial Sloan Kettering’s Regional Skin Cancer Clinic, Hauppauge, New York, United States of America.
- **Professor Ronald Rapini**, Chernosky Distinguished Professor and Chair of the Department of Dermatology and Professor of Pathology, University of Texas Medical and Chair of the Department of Dermatology and Professor of Pathology, MD Anderson Cancer Center, Texas, United States of America.
- **Dr Scott Fosko**, Consultant and Chair of the Department of Dermatology, Mayo Clinic, Florida, Adjunct Professor, Department of Dermatology and Saint Louis University Center for Outcomes Research, Saint Louis University School of Medicine, Missouri, United States of America.

The meeting has been strongly supported by the pharmaceutical and allied health industries as sponsors and trade exhibitors. I invite all delegates to visit the displays in the trade exhibition, to meet the industry representatives and to learn about new developments in products and services. It is with the very generous support of our sponsors and exhibitors that the College is able to hold a meeting of this size and quality.

I hope you all find this meeting a worthwhile and enjoyable experience.

Associate Professor Christopher Baker, FACD
Associate Professor Christopher Baker
Dr Andrew Miller
Dr Andrew Satchell
Dr Adrian Lim
Associate Professor Saxon Smith
Dr Alan Donnelly
Dr Robert I. Kelly
Dr Anne Lewis
Dr Michael Pitney

President
President-Elect
Honorary Secretary
Dean of Education
Elected Director (NSW)
Elected Director (WA)
Elected Director (VIC)
Elected Director (SA)
Elected Director (QLD)

NEW SOUTH WALES FACULTY
Dr N.S. Agar
Dr P. Alexander
Dr F.E. Anderson*
Dr R.P. Armati
Dr P. Artemi
Dr N. Aspres
Dr S. Bakis-Petsoglou
Dr M. Bannister
Emer. Prof. R.St.C. Barnetson
Dr L.D. Bear
Dr G. Becker
Dr P. Brown
Dr G.D. Cains
Dr H. Chan
Dr J.C. Chapman
Dr P.G. Chee
Dr K. Chen
Dr J.Y.J. Choi
Dr E.Y.Y. Chow
Dr R. Coccioletone
Cl. A/Prof. C.A. Commens
Dr D.K. Cook
Dr N. Cook
Prof. A.J. Cooper, OAM
Dr G. Cottee
Dr A.E. Cronin*
Dr K.A. Crotty
Prof. D.L. Damian
Dr D.E. Davies
Dr E. Dawes-Higgs
Dr J.W. de Launey
Dr W.E. de Launey
Dr R.W. Denisenko
Dr S. de Zwaan
Dr E. Doherty
Dr S. Donoghue
Dr C.J. Drummond
Dr K.J. Dunlop
Dr P.K. Dwyer

Dr K. Engeti
Dr H. Fallah
A/Prof. P. Fernandez-Peñas
A/Prof. G. Fischer, AM
Dr J. Fisher
Dr B. Florance, RFD, RD*
Dr P.C. Frederiksen
Dr P.A. Freeman
Dr S. Freeman
Dr J. Frew
Prof. K. Georgouras, OAM
Dr D. Gillam (deceased 6 October 2016)
Dr R. Gillespie
Dr T.K. Gilmour
Dr G. Gottschalk
Dr E. Gow
Dr I. Grigoris
Dr K. Gudmundsen
Dr P. Guitera
Dr M. Gupta
Dr R. Gupta
Dr I.D. Hamann
Dr R.S. Hannaford
Dr R. Harvey
Dr M.F. Healsmith
Dr S. Heiman
Dr K.K-L. Ho
Dr P. Hogan
Dr D. Holt
Dr E. Hong
Dr R. Howes
Dr M.J. Hunt
Dr N.T. Huynh
Dr F. Isaacs
Dr N. Jiang
Dr D. Jenkins
Dr M. Jones-Caballero
Dr S. Kalouche
Dr C.R. Kearney
Dr S. Khurana
Dr A. Kline
Dr C. Koh
Dr J. Konya

A/Prof. S. Kossard
Dr J.F.C. Krivanek
Dr J.M. Kuchel
Dr A. Kumar
Dr A. Kurien
Dr A-M. Kurzydlo
Dr E. Lamrock
Dr W.A. Land, AM, RFD, AE
Dr M.M. Lane-Brown
Dr K.H. Le
Dr M-L. Lee
Dr M-S. Lee
Dr M. Lee
Dr P.A. Lee
Dr S.H. Lee
Cl. Prof. S. Lee, AM
Dr J.L. Le Guay
Dr M. Leibowitz
Dr L.J. Leow
Dr J. Lewis
Dr M. Li
Dr A. Lim
Dr P. Lim
Dr T.K. Lipscombe
Dr M. Llewellyn
Dr E. Lobel
Dr M.S. Loghdey
A/Prof. P.M. Lowe
Dr J. Mackay
Dr A.R. Mackenzie-Wood
Dr L. Martin
Dr J. Matulich
Dr I.D. McCrossin
Dr R.R.A. McDonald
Dr S. McDonald
Dr B. McGaw*
Dr C. McKay
Dr M. McRae
Dr A.C. Miller
Dr A. Ming
Dr G. Moreno Bonilla
Dr C. Morrow
Dr A.St.L. Moss
Dr E. Mullan
Prof. D. Murrell
Dr S.Y. Ng
Dr R.T.D. Nguyen
Dr A. O’Neill
Dr C.S-C. Ong
Dr V. Padman
Dr B.K-C. Pang
A/Prof. K. Parsi
Dr A. Patel
Dr A. O’Neill
Dr C.S-C. Ong
Dr V. Padman
Dr B.K-C. Pang
A/Prof. K. Parsi
Dr A. Patel
A/Prof. R.D. Paver
Dr R.D. Peek
Dr T.A. Phan
Dr T.S.C. Poon
Dr E. Pritchard
Dr V. Pua
Dr W. Regan, AM
Dr J.P. Relic
Emer. Prof. S.W. Richards
Dr C.A. Riordan
Dr J. Robinson
Dr M. Rogers
Dr R.H. Rosen
Dr R. Rubel
Dr W.J. Ryman
Dr L. Sagi
Dr R.M. Salmon
Dr A. Satchell
Dr A. Saywell
Dr L. Saywell
Dr D. Sebaratnam
Dr A.C.Y. See
Dr J-A. See
Dr J.F. Shannon
A/Prof. S.P. Shumack, OAM
Dr S.E. Sinclair
Dr J.R.A. Sippe
Dr G. Sivapirabu
Dr A. Smith
Cl A/Prof. S. Smith
Dr S.K. Sohal
Cl A/Prof. D.G. Stanford
Dr K.M. Stapleton
Dr E. Starritt
Dr A. Steele-Smith
Dr J. Steele-Smith*
Dr R.B.H. Stephens
Dr M. Stewart
Dr N. Stewart
Dr H.M. Studniberg
Dr J.R. Sullivan
Dr M.C. Symons
Dr M. Tam
Dr F.J. Tefany
Dr K.E. Thai
Dr C.H.F. Thoo
Dr N. Todes-Taylor
Dr A. Tomizawa
Dr A. Varol
Dr S. Venugopal
Dr E. Waite
Dr B. Wallace
Dr R. Watther
A/Prof. O. Wargon, OAM
Dr R. Watchorn
Dr A.B. Watson
Dr G.C. Watt
Dr A. Wegman
Dr P.A. Weller
Dr J. Wells
Prof. W. Weninger
Dr L. Wheeler
Dr H.A.D. White, AM, RFD
Dr M. Whitfeld
Dr E. Willsteed
Dr N. Wines
Dr R. Wittal
Dr D.Y-S. Wong
Dr D.A. Wong
Dr K.C-W. Wong
Dr L-C.F. Wong
Dr G. Wood, AM
Dr J. Woods
Dr E. Yiassemides
Dr J. Yip
Dr I.R. Younger
A/Prof. S.S. Zagarella
Dr M.W. Harley
Dr A. Herat
Dr R.J. Hills
Dr G.J. Holmes
Dr B. Jones
Dr L.J. Kelly*
A/Prof. K. Khoostehrani
Dr Y.J. Kim
Dr S. Kumar
Dr Y.N. Lau
Dr C.T. Lee
Dr K-C. Lee
Dr Y. Lee
Dr D.F. Leslie
Dr D. Lim
Dr K.R. Lun
Dr S. Manoharan
Dr I. Mc Coll
Dr P.L. Mc Laran
Dr E. McMeniman
Dr C.H. Mercer
Dr R.M. Millar
Dr R. MacD. Miller
Dr A.B. Mirza
Dr J.B. Muir
Dr A.J.D. Mulholland
Dr R.R. Noakes
Dr M.A. Oziemski
Dr S.M. Ozluer
Emer. Prof. J.A. Pagliaro
Dr C. Petherbridge*
Dr M.J. Pitney
Dr W.W. Pruim
Dr S. Reid
Dr I.M. Robertson
Dr K.H. Rodins
Dr C. Sander
Dr M.S. Saywell
A/Prof. H. Schaider
Dr S. Scuderi
Dr M.P. Sharkey
Dr V.L. Shepherd
A/Prof. G.M. Siller
Dr P.R. Sinclair
Dr R.J. Sinclair
Prof. H.P. Soyer
Dr L.J. Speelman
Dr G.J. Stephenson
Dr D. Surjana
Dr P. Teng
Dr S. Tritton
Dr S. Tucker
Dr Y.Y. Vun
Dr G.H. Wagner
Dr S.D. Waite
Dr M. Warren
Dr S. Webber
Dr J.W. Wells
Dr L. Wheller
Dr P.R. Wilson
Dr J.K-H. Wu
Dr S.A. Yong-Gee
Dr C. Yoong
Dr L. Young
Dr T. Zappala

QUEENSLAND FACULTY

Dr C.D.Y. Adib
Dr M.L. Andrews
Dr J.C. Auld
Dr H. Avery
Dr S. Baghaei
Dr L. Banney
Dr K.E. Behne
Dr I. Browne
Dr D. Burdon-Jones
Dr G.J. Butler
Dr J.L. Byth
Dr B. Carew
Dr M. Carroll
Dr T. Casey
Dr J.E.D. Chick
Dr K-Y. Choong
Dr D. Coates
Dr J.G. Coates
Dr N.J. Collins
Dr B-I. Cominos
Dr S. Congdon
Dr S.L. Conias
Dr C. Curchin
Dr T.A. Darben
Dr S. Davidson
Dr B.J. DeAmbrosis
Dr K. DeAmbrosis
Dr R.M. De Voss
Dr A.J. Dore
Dr C.F. Faulkner
Dr D.B. Francis
Dr M.G. Freeman
Dr G. Frost
Dr D. Gaffney
Dr Z.S. Gaspar
Dr R. Gild
Dr A.M. Godbolt
Prof. N. Haass

SOUTH AUSTRALIAN FACULTY

Dr S. Anabarasa
Dr P. Armenteros
Dr S. Ball
Dr C. Black
Dr M. Black
Dr G. Casey
Dr E. Christou
Dr R.M. Czechowicz
Dr C. M. Duguid
Dr E. Ellis
Dr L. Gordon
Dr N.L. Grieve
Dr M.J.A. Hanna
Dr E. Haveroth
Dr D.C. Hill
A/Prof. S.C. Huilgol
Dr S. Khoury
Dr K.J. Koh
Dr Y-C. Lee
Dr A.E. Lewis
Dr D. Long
Dr H. Ly
Dr R. Manifold
Dr G. Marshman
Dr J. Menz
Dr S.C. Murray
Dr K. Newland
Dr J. Nicolson
Dr V.F. O’Brien
Dr C.G-G. Ooi
Dr C.J. Parker
Dr A.L. Pearce
Dr C. Reid
Dr C. Ross
Dr E. Ryan
Dr P.A. Selva-Nayagam
Dr K. Shirato
Dr S.K. Sidhu
Dr I.J. Simmons
Dr D. Tilakaratne
Dr C.J. Tyson
Dr S. Vaidya
Dr P.C. Walker
Dr L.J. Warren

VICTORIAN FACULTY

Dr A.N.R. Amerasinghe
Dr K. Armour
A/Prof. C.S. Baker
Dr J. Banky
Dr P.S. Bekhor
Dr P.A. Berger
Dr F. Bhahba
Dr N.R. Bleasel
Dr T. Bohl
Dr A. Boyapati
Dr A. Boyce
Dr A. Braue
Dr B. Breadon
Dr S.K. Brennand
Dr F.J. Bruce
Dr J.C. Burford
Dr J.M. Butler, AM
Dr J. Cahill
Dr A.W. Callan
Dr N.J. Callan
Dr J. Cargnello
Dr A. Catona
Dr A.J. Chamberlain
Dr S. Chandra
Dr V. Chitreddy
Dr A.H.O. Chong
Dr A.C. Ciconte
Dr T.J. Connors
Dr P.S.J. Cowen
Dr R.B. Crouch
Dr P.A. Curnow
Dr M. Darling
Dr R. De Cruz
Dr R.L.S. Dickinson
Dr H. Dinh
Dr C. Dolianitis
Dr N.P. Downes
Dr R. Dunn
Dr D. Dyall-Smith
Dr S. Eisman
Dr B.R. Entwistle*
Dr P.E. Fergin
Dr A. Fitzgibbon
A/Prof. P.A. Foley
Dr D. Gan
Dr D.V. Gill
A/Prof. S. Gilmore
A/Prof. D. Gin
Dr M.S.Y. Goh
A/Prof. G.J. Goodman
Dr J. Green
Dr C. Grills
Dr S. Gunathesan
Dr S. Gupta
Dr L.R.S. Hale
A/Prof. A.P. Hall
Dr S.C. Harrison
Dr M.I. HASKett
Dr E. Hiscutt
Dr J. Horton
A/Prof. Dr A. Howard
Dr C. Jalilian
Dr W.J. Jamieson* (deceased 12 March 2017)
Dr A. Jevtic
Dr A. Jopp-McKay
Dr S. Joseph
Dr J.R. Kelly*
Prof. J.W. Kelly
Dr R.I. Kelly
Dr J. Kern
Dr P.J. Lane
Dr D. Lancer
Dr A. Lasocki
Dr A.Y.L. Lee
Dr M.W-K. Lee
Dr S-W. Lim
Dr W. Liu
Dr L. Ly
Dr G. Lyons
Dr E. Ma
Dr R. Mak
Dr A.W-Y. Mar
Dr V. Mar
Prof. R. Marks, AM
Dr D.M. McColl
CL A/Prof. C.J. McCormack
Dr C. McDonald
Dr C.J. Meehan
Dr A.C. Michaelides
Dr O. Milne
Dr M. Mohamed
Dr E. Mooney
Dr V.A. Morgan
Dr M.L.L. Moyle
Dr J. Ng
Dr R. Nguyen
Dr J. Nicolopoulos
A/Prof. R. Nixon
Dr D.S. Nurse*
Dr T.J. O’Brien
Dr R.J. O’Keefe
Dr M. O’Loughlin
Dr J.M. Opie
Dr D.C. Orchard
Dr M. Palmer
Dr V. Palmer
Dr Y. Pan
Dr A. Perez De Velasco
Dr E.C-H. Poon
Dr B. Rajagopalan
Dr D. Rathnayake
Dr G.J. Rennick
Dr J. Rhodes
Dr M.V. Rich
Dr H. Roberts
Dr S. Robertson
Dr M.A. Rodrigues
Dr G.L. Ross
Dr A. Rudd
Dr R. Ruiz Araujo
Dr T.J. Rutherford
Dr K. Sandhu
Dr H.L. Saunders
Dr L.V. Scardamaglia
Dr C.E. Scarff
Dr C. Schofield
Dr A.H. Segal
Dr M. Seith
Dr N. Sharma
Dr P. Sharma
Dr D.A.R. Shephard
Dr A. Sheridan
Dr N. Shim
Dr P.A. Sinclair
Prof. R.D. Sinclair
A/Prof. M.J. Sladden
A/Prof. J.C. Su
Dr B. Swan
Dr E.H. Toft, AM*
Dr M.M. Tam
Dr B.T. Tan
Dr E. Tan
Dr B.J. Tate
Dr A. Tuxen
Dr E.J.Mck. Upjohn
Prof. G.A. Varigos
Dr A. Verma
Dr E. Veysey
Dr R. Vyas
Dr F. Y.Y. Watkins
Dr M.R. Webster
Dr B.M. Welsh
Prof. I. Winship
Dr K. Wolfowitz
Dr A. Wright
Dr L-M. Yap
Dr A. Yazdabadi
Dr J.M. Yeatman
Dr L. Yip

WESTERN AUSTRALIAN FACULTY
Dr J. Adamson
Dr J.H. Allison*
Dr A. Anderson
Dr K. Borchard
Dr R. Brand
Dr T. Caccetta
Dr J.J.S-M. Chan
Dr P. Cherian
Dr H.C. Chua
Dr C. Clay
Dr J. Cole
Dr B.L. Connor
Dr K.J. Dallimore
Dr T.A. Delaney
Dr A.M. Donnelly
Dr T.G. Elliott
Dr R. Foster
Dr G. Foxton
Dr H. Gebauer
CL A/Prof. K. Gebauer
Dr R. Granger
Dr A.R. Halbert
Dr W.K. Hedley
Dr D. Hitching
Dr C. Clay
Dr A. Wright
Dr J.J. Yeaton
Dr L. Yip

OVERSEAS
Dr N. Abbott
Prof. C. Anderson
Dr S. Arnold
Dr T. Carner
Dr E. Finkelstein
Dr J. Foo
Dr M. Heng
Dr M. Lowes
A/Prof. F. Moloney
Dr A. Saracino
Prof. W. Sinclair
Dr F. van der Walt
Dr M. Wade

RESIDENT IN NEW ZEALAND
Dr J.D. Adams
Dr L.M. Armstrong* (SA Faculty)
Dr W.J. Burton
(NSW Faculty)
Dr T. Gunson (WA Faculty)
Dr M.W. Hursthouse (SA Faculty)
Dr D. Rowan
(SA Faculty)
Dr D. Sears
Dr B.C. Turnbull* (SA Faculty)
Dr D.W. Young (VIC Faculty)

* Foundation Members
HONORARY MEMBERS

CL. Prof. C.L. Goh ________ Singapore
Dr. J. Hawk ________ United Kingdom
Prof. P. Mortimer ________ United Kingdom
Prof. E. Tschachter ________ Austria

ASSOCIATE MEMBERS

Dr. T.W. Beer ________ Western Australia
Dr. B. Bullpitt ________ New South Wales
Dr. K.C. Chong ________ Queensland
Dr. E.C. Cleary ________ South Australia
Dr. R. Crouch ________ New South Wales
Dr. A. Darling ________ Victoria
Dr. A.P. Dorevitch ________ Victoria
Dr. J.P. Dowling ________ Victoria
Dr. R.E.T. Duhig ________ Queensland
Dr. B. Dutta ________ New South Wales
Dr. R.B. Dymock ________ South Australia
A/V Prof. D. Ellis ________ South Australia
Dr. J. Farnsworth ________ Queensland
Dr. A. Fischer ________ New South Wales
Dr. D.S. Forbes ________ New South Wales
Dr. J. Fryer ________ New South Wales
Dr. A. Gramp ________ South Australia
Dr. W.A.D. Griffiths ________ United Kingdom
Prof. G. Halliday ________ New South Wales
Dr. P.J. Heenan ________ Western Australia
Dr. V.C. Howard ________ New South Wales

Dr. C. James ________ South Australia
Dr. B. Kynaston ________ Queensland
Dr. J. Magee ________ Victoria
Dr. S. Mann ________ New South Wales
Dr. G. Mason ________ Victoria
Miss R. McAleer, AM ________ Western Australia
Prof. S. Menziesv ________ South Australia
Dr. D. Muir ________ New South Wales
Prof. H.K. Muller ________ Tasmania
Prof. R. Penny, AO ________ New South Wales
Prof. H.M. Princev ________ Victoria
Dr. A. Ryan ________ Victoria
Dr. G. Strutton ________ Queensland
Dr. J. Sullivan ________ Queensland
Dr. S. Swain ________ Victoria
Dr. J. Tversky ________ Victoria
Prof. D. Weedon, AO ________ Queensland
Dr R.A. Williams ________ Victoria
Prof. K. Wolff ________ Austria
CL. A/Prof. L. Yu ________ Western Australia

*Estimated 777,000+ patient-years of cumulative exposure from 7+ years’ clinical use.1 In psoriasis. 5 years PASI 75/90 response data,1,3 5+ years safety observations,3,5 4 times a year dosing (after 2 initial doses).1


REFERENCES:
PROGRAM

The plenary sessions will be held in the Pyrmont Theatre. Concurrent sessions will be held on level 2 across the Meeting and Parkside rooms.

SPECIAL EVENT

The following satellite meeting is being held in association with the College ASM:

AUSTRALIAN DERMATOLOGY NURSES’ ASSOCIATION 16TH ANNUAL NATIONAL CONFERENCE

International Convention Centre Sydney
Saturday 6 May and Sunday 7 May 2017

REGISTRATION

The registration desk will be located in the Pyrmont Theatre Foyer. The registration desk will open on Saturday 6 May from 0700 and throughout the meeting.

The College secretariat office located in Meeting Room C2.4 will be open from 1000 to 1600 daily.

MEET THE ACD STAFF!

The College will have its own stand at booth 111-114 in the trade exhibition, manned by members of the College staff.

Come meet us and find out what we can do for you. Pick up some leaflets, find out about the website and check up on your Continuing Professional Development (CPD) points.

NAME BADGES

Name tags must be worn at all times. Delegates without a name badge may be refused entry to sessions and to the trade exhibition.

CONFERENCE APP

The College is offering a free downloadable app for the Annual Scientific Meeting. To download the app please search for ACD2017ASM in your app store. The app can also be viewed in a web browser at acd2017asm.mobi.

Features of the app include:

- Building your own personal program of sessions. Note that recording your session selections on the app does not confirm your attendance at any of the social functions or sponsored symposia sessions. Please see staff at the ASM registration desk if you have not pre-registered for these sessions and wish to attend.
- Participating in the exhibition passport competition
- View all trade details and easily be able to contact them after the ASM
- All delegates will have a QR code on their name badge which can then be used by trade to collect your details to be able to send you further information.

Please see the staff at the registration desk if you are having any issues with using the app.
**EXHIBITOR PASSPORT COMPETITION**

This year the exhibitor passport competition will be run through the conference app. Each trade exhibitor will have a sign at their booth with a QR code. To enter the competition for each booth:

1. Scan the barcode at the exhibition booth using the scan function in the menu of the app. Note that you must allow the app to access your phone’s camera.
2. A question about the exhibitor will pop up, please answer this question to submit for entry for this booth.
3. You can view all of the exhibitors you have answered questions for in the Exhibitor Passport Entries.

Note that once an answer is submitted you cannot go back to view or change this.

Delegates are required to answer 20 exhibitor questions to qualify for a complete entry. Prizes will be awarded during the lunch break on Tuesday 9 May in the Exhibition Hall. **Open only to dermatologists and vocational trainees in dermatology.**

**TRADE EXHIBITION**

The trade exhibition will be in Hall 1. It will be open on the following days:

- **Saturday 6 May** from 1000 to 1600 (1245 official opening)
- **Sunday 7 May** from 1000 to 1600
- **Monday 8 May** from 1000 to 1600
- **Tuesday 9 May** from 1000 to 1345

The morning tea, lunch and afternoon tea breaks will be held in the trade exhibition. **Please note that separate dietary catering tables will be set up in the exhibition area for those who have submitted dietary requests.**

**AWARDS FOR OUTSTANDING EXHIBITORS**

Awards for the outstanding exhibits will be announced on Tuesday 9 May 2017. The categories of award are:

- Most outstanding display of 9 sqm or less in size
- Most outstanding display of 18 sqm to 27 sqm in size
- Most outstanding display of 36 sqm in size, or larger

The award will be decided by a panel of judges.

---

**SPEAKERS’ PREPARATION ROOM**

The speakers’ preparation room is located in Meeting Room C2.1 of the International Convention Centre Sydney. The room is staffed daily. The technician will be on hand one hour before the start of each session, then 30 minutes after the close of the final session. Presenters are encouraged to hand their presentations in at least two hours before required onstage, or the day before if presenting in the morning.

**AWARDS**

If there are papers of sufficient merit, the following awards/prizes will be awarded:

- Best research paper read at the Annual Scientific Meeting – F. & E. Bauer Foundation Prize
- Best paper in the Registrars’ Forum Kindly sponsored by **Galderma**
- Best poster presentations (two prizes) Kindly sponsored by **AAAF**
- Best paper or poster presentation by a New South Wales Registrar, the Eileen Collins Memorial Prize – funded by the New South Wales Faculty
- Best paper in Contact Dermatitis, the John Fewings Memorial Prize – funded by the Skin & Cancer Foundation Victoria
Cosentyx Efficacy

He was so excited to have been given a greater opportunity to achieve clear skin

*At week 52, PASI 100 responses to secukinumab and ustekinumab were 46.9% and 35.8% respectively (p=.0103). Primary study endpoint was achieved with secukinumab demonstrating superiority in PASI 90 response (79%) to ustekinumab (57.6%; p<.0001) at Week 16.

That’s Cosentyx

PBS Information: Section 85 Authority Required for the treatment of severe chronic plaque psoriasis, active ankylosing spondylitis and severe psoriatic arthritis.

Refer to PBS Schedule for full Authority information.

See approved Product Information before prescribing. Approved Product Information available on request. For the most up-to-date Product Information, go to: https://www.novartis.com.au/products/healthcare-professionals

COSEN™ (secukinumab) Indication: Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. Treatment of adult patients with active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate. Treatment of adult patients with active ankylosing spondylitis.

Dosage and administration: Plaque psoriasis: The recommended dose is 300 mg by subcutaneous injection with initial dosing at weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Psoriatic arthritis: The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeeks 0, 1, 2, 3, followed by monthly maintenance dosing starting at Week 4. For patients who are anti-TNFα inadequate responders or patients with concomitant moderate to severe plaque psoriasis, the recommended dose is 300 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4. Each 300 mg dose is given as two subcutaneous injections of 150 mg. Ankylosing spondylitis: The recommended dose is 150 mg by subcutaneous injection with initial dosing at Weeks 0, 1, 2 and 3, followed by monthly maintenance dosing starting at Week 4.

Contraindications: Severe hypersensitivity reactions to the active substance or to any of the excipients. Clinically important, active infections.

Precautions: Infections: Caution in patients with chronic or history of recurrent infection. If a patient develops a serious infection, the patient should be closely monitored and Cosentyx should not be administered until the infection resolves. Anti-tuberculosis therapy should be considered prior to initiation in patients with latent tuberculosis. Cosentyx should not be given to patients with active tuberculosis. Crohn’s disease: Caution should be exercised when prescribing to patients with inflammatory bowel disease. Exacerbations, in some cases serious, occurred during clinical trials in plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. In addition, new onset inflammatory bowel disease cases occurred in clinical trials. Patients should be monitored for signs and symptoms of inflammatory bowel disease. Hyperesensitivy reactions: Rare cases of anaphylactic reactions have been observed during clinical trials. Administration should be discontinued immediately and appropriate therapy initiated if an anaphylactic or other serious allergic reaction occurs. Latex-sensitive individuals: The removable cap of the Cosentyx pre-filled syringe contains a derivative of natural rubber latex. Vaccinations: Cosentyx should not be given concurrently with live vaccines. Pregnancy: Caution should be exercised during pregnancy only if the benefits clearly outweigh the potential risks. Breast-feeding: Caution should be exercised when Cosentyx is administered to a woman who is breast-feeding. Interactions: Live vaccines should not be given concurrently with Cosentyx.

Side effects:

Very common (≥10%): nasopharyngitis. Common (1 to 10%): upper respiratory tract infection, rhinitis, pharyngitis, oral herpes, diarrhoea, urticaria, rhinorrhoea, headache, nausea, hypersplenomegaly. Uncommon (0.1 to 1%): sinusitis, tonsillitis, oral candidiasis, neutropenia, tinea pedis, otitis externa, conjunctivitis. In clinical trials, major adverse cardiovascular events were rarely observed in patients receiving secukinumab. In the overall secukinumab program, the exposure adjusted incidence rates of adjudication-confirmed cases per 100 patient-years for secukinumab was 0.40 versus 0.39 for placebo. Elevations (mainly CTCAE Grade 1 and Grade 2) in cholesterol, triglycerides and hepatic transaminases were also observed during clinical trials in patients with psoriatic arthritis and ankylosing spondylitis. (c0171016 m). Reference: 1. Blauvelt A, et al. JAAD 2016. http://dx.doi.org/10.1016/j.jaad.2016.08.008. © Registered trademark of Novartis. Novartis Pharmaceuticals Australia Pty Limited ABN 18 004 244 103, 54 Walkerlo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. Date of preparation: March 2017. AU-1489. CRD2756.
The ASM sessions will be held on Level 2 of the Convention Centre and the trade exhibition in Hall 1 of the Exhibition Centre of the ICC Sydney.
ROOM ALLOCATIONS

- Pyrmont Theatre: ASM Plenary and Concurrent Sessions
- Pyrmont Theatre Foyer: ASM Registration Desk and College History Display
- Meeting Room C2.1: Speaker Preparation Room
- Meeting Room C2.2 and C2.3: ADNA 16th National Conference Sessions and Moh’s Surgery Session
- Meeting Room C2.4: College Secretariat
- Meeting Room C2.5: Meeting Room
- Meeting Room C2.6: Meeting Room
- Parkside 1: Conference Dinner
- Parkside 2: ASM Concurrent Sessions
- Hall 1: Trade Exhibition

ACCESS TO THE ICC SYDNEY

PUBLIC TRANSPORT AND TAXIS

The ICC Sydney is located in the heart of Sydney’s Darling Harbour. ICC Sydney is easily accessible by public transport, including light rail, ferry and train and is only a 10 minute walk from Central and Town Hall train stations. Taxis are available at all times throughout the inner city.

PARKING

Address:
14 Darling Drive, Sydney, NSW 2000
ICC Sydney Exhibition Centre Car Park
(Car Park 1)
Proceed to Level 2 in the lift.

Operating hours:
Monday to Sunday - 24 hours

Parking rates:
0 - 1 hour $18.00
1 - 2 hours $30.00
2 - 3 hours $38.00
3 - 4 hours $44.00
4+ hours $49.00
Lost ticket $49.00
Per entry per day
Night rate $28.00
Entry after 6pm and exit before 4.00am
Return buses have been organised to transport delegates to/from The University of Sydney for the Conferring Ceremony. Please proceed to Iron Wharf Place outside the Convention Centre of the ICC Sydney with buses departing regularly from 1545-1645.

Buses will depart regularly from the University starting at 1900 (returning to the ICC Sydney). Last bus departs at 2015.
The Convenor of the scientific program is Associate Professor Samuel Zagarella, supported by Dr Ian Hamann and Dr Monisha Gupta as Co-Convenors and the Scientific Meetings Steering Committee of the College.

### SATURDAY 6 MAY 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0830-0845</td>
<td>OPENING BY PRESIDENT AND WELCOME TO COUNTRY</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>0845-1015</td>
<td>PLENARY SESSION 1</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1015-1030</td>
<td>MORNING TEA</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1030-1030</td>
<td>ADNA MEETING</td>
<td>Meeting Rooms C2.2 and C2.3</td>
</tr>
<tr>
<td>1030-1100</td>
<td>MORNING TEA</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1045-1230</td>
<td>MORNING TEA</td>
<td>Meeting Rooms C2.2 and C2.3</td>
</tr>
<tr>
<td>1100-1230</td>
<td>REGISTRARS’ AND FELLOWS UPDATE</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1230-1345</td>
<td>LUNCH</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1345-1515</td>
<td>SURGERY UPDATE FOR GENERAL DERMATOLOGISTS 1345-1515</td>
<td>Parkside 2</td>
</tr>
<tr>
<td>1345-1515</td>
<td>SURGERY UPDATE</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1515-1600</td>
<td>AFTERNOON TEA</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1600-1730</td>
<td>REGISTRARS’ AND FELLOWS UPDATE 1600-1730</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1730-1830</td>
<td>SPONSORED SYMPOSIUM</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1730-1830</td>
<td>MOHS SURGERY SESSION 1730-1930</td>
<td>Rooms C2.2 and C2.3</td>
</tr>
</tbody>
</table>

### SUNDAY 7 MAY 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730-0830</td>
<td>ACNE SESSION</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>0900-1030</td>
<td>CONTACT DERMATITIS SESSION 0900-1030</td>
<td>Meeting Rooms C2.2 and C2.3</td>
</tr>
<tr>
<td>0845-1015</td>
<td>PSORIASIS SYMPOSIUM</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>0845-1015</td>
<td>GLOBAL DERMATOLOGY SYMPOSIUM</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1015-1100</td>
<td>MORNING TEA</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1030-1100</td>
<td>ADNA MORNING TEA</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1100-1230</td>
<td>PLENARY SESSION 2</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1230-1345</td>
<td>LUNCH</td>
<td>Pyrmont Theatre</td>
</tr>
<tr>
<td>1345-1515</td>
<td>SURGERY UPDATE FOR GENERAL DERMATOLOGISTS 1345-1515</td>
<td>Parkside 2</td>
</tr>
<tr>
<td>1345-1515</td>
<td>CLINICOPATHOLOGICAL PATHOLOGICAL CORRELATION 1345-1515</td>
<td>Parkside Theatre</td>
</tr>
<tr>
<td>1515-1600</td>
<td>AFTERNOON TEA</td>
<td>Trade Exhibition - Hall 1</td>
</tr>
<tr>
<td>1700-1900</td>
<td>CONFERRING CEREMONY</td>
<td>Great Hall, University of Sydney</td>
</tr>
<tr>
<td>1700-1900</td>
<td>FOUNDERS’ COCKTAIL PARTY</td>
<td>MacLaurin Hall, University of Sydney</td>
</tr>
</tbody>
</table>

*Program subject to change*
**MONDAY 8 MAY 2017**

- **GENITAL DERMATOLOGY**
  0730-0830
  Pyrmont Theatre

- **PAEDIATRIC DERMATOLOGY**
  0730-0830
  Parkside 2

- **MEDICAL DERMATOLOGY UPDATE**
  0845-1015
  Pyrmont Theatre

- **ART OF DERMATOLOGY AND OTHER SURPRISES**
  0845-1015
  Parkside 2

- **MORNING TEA**
  1015-1100
  Trade Exhibition - Hall 1

- **PLENARY SESSION 3**
  1100-1230
  Pyrmont Theatre

- **LUNCH**
  1230-1345
  Trade Exhibition - Hall 1

- **ETHICS AND PROFESSIONALISM CONGRESS**
  1345-1515
  Pyrmont Theatre

- **AFTERNOON TEA**
  1515-1600
  Trade Exhibition - Hall 1

- **ETHICS AND PROFESSIONALISM CONGRESS**
  1600-1645
  Pyrmont Theatre

- **ACD ANNUAL GENERAL MEETING**
  1645-1730
  Pyrmont Theatre

- **SPONSORED SYMPOSIUM**
  1730-1830
  Pyrmont Theatre

**TUESDAY 9 MAY 2017**

- **REGISTRARS’ FORUM**
  0730-0830
  Pyrmont Theatre

- **DERMATOLOGY HOSPITALISTS SESSION**
  0730-0830
  Parkside 2

- **NON-MELANOMA SKIN CANCER SYMPOSIUM**
  0845-1015
  Pyrmont Theatre

- **COSMETIC DERMATOLOGY FOR GENERAL DERMATOLOGISTS**
  0845-1015
  Parkside 2

- **MORNING TEA**
  1015-1100
  Trade Exhibition - Hall 1

- **PLENARY SESSION 4 AND AWARDING OF PRIZES**
  1100-1230
  Pyrmont Theatre

- **LUNCH**
  1230-1345
  Trade Exhibition - Hall 1

- **WHAT’S NEW IN JOURNALS**
  1345-1515
  Pyrmont Theatre

- **FREE PAPERS**
  1345-1515
  Parkside 2

*Program subject to change*
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0700-1700</td>
<td><strong>REGISTRATION DESK OPEN</strong></td>
<td></td>
</tr>
<tr>
<td>0830-0845</td>
<td><strong>WELCOME TO COUNTRY OPENING BY PRESIDENT</strong></td>
<td>Ms Y. Weldon</td>
</tr>
<tr>
<td></td>
<td>Room: Pyrmont Theatre</td>
<td>A/Prof. C. Baker</td>
</tr>
<tr>
<td>0845</td>
<td><strong>PLENARY SESSION 1</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room: Pyrmont Theatre</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: A/Prof. C. Baker</td>
<td></td>
</tr>
<tr>
<td>0845</td>
<td>Dr A. Marghoob</td>
<td>Nevogenesis: Insights gained from dermoscopy</td>
</tr>
<tr>
<td>0905</td>
<td>Dr S. Fosko</td>
<td>Targeted therapy comes to basal cell carcinoma: Hedgehog inhibitors</td>
</tr>
<tr>
<td>0925</td>
<td>Prof. R. Rapini</td>
<td>Diagnostic criteria in dermatology</td>
</tr>
<tr>
<td>0945</td>
<td>Prof. A. Anstey</td>
<td>Transformative case reports in dermatology: Hunting for the needle in the haystack</td>
</tr>
<tr>
<td>1005</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>1015</td>
<td>END OF SESSION</td>
<td></td>
</tr>
<tr>
<td>1015-1100</td>
<td>MORNING TEA IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
</tr>
<tr>
<td>1100-1230</td>
<td><strong>REGISTRARS’ AND FELLOW UPDATE SESSION 1</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room: Pyrmont Theatre</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr I. Hamann</td>
<td></td>
</tr>
<tr>
<td>1100</td>
<td>Dr A. Marghoob</td>
<td>Benefits of leveraging technology towards melanoma detection</td>
</tr>
<tr>
<td>1120</td>
<td>A/Prof. P. Guitera</td>
<td>ANZMTG 02.12 the RADICAL trial – RADiotherapy or imiquimod in complex lentigo mALigna</td>
</tr>
<tr>
<td>1132</td>
<td>Dr D. Kennedy</td>
<td>Dermatology and medications in women of childbearing age</td>
</tr>
<tr>
<td>1144</td>
<td>Dr E. McMeniman</td>
<td>Update on hidradenitis suppuritiva</td>
</tr>
<tr>
<td>1156</td>
<td>Dr A. Saracino</td>
<td>Update on cutaneous lupus erythematosus</td>
</tr>
<tr>
<td>1208</td>
<td>Dr N. Wines</td>
<td>Advances in obstetric dermatology</td>
</tr>
<tr>
<td>1220</td>
<td>Questions</td>
<td></td>
</tr>
<tr>
<td>1230</td>
<td>END OF SESSION</td>
<td></td>
</tr>
<tr>
<td>1230-1345</td>
<td>LUNCH IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Room</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------</td>
<td>-----------------------</td>
</tr>
</tbody>
</table>
| 1345-1515 | **REGISTRARS’ AND FELLOW UPDATE SESSION 2** | Pyrmont Theatre       | Dr. M. Gupta      | A/Prof. M. Schifter: Oral medicine for dermatologists: Oral manifestations and complications of dermatological diseases  
|        |                                               |                       |                   | Dr K. Kerkemeyer: Lichen planopilaris: A retrospective study of 32 cases in an Australian tertiary referral hair clinic  
|        |                                               |                       |                   | Dr. L. Yip: Alopecia update  
|        |                                               |                       |                   | Dr M. Rodrigues and Dr M. Gupta: Update vitiligo and other pigmentary disorders  
|        |                                               |                       |                   | Dr E. Forward: Treatment of rosacea: Update on general management approach and topical treatment options  
|        |                                               |                       |                   | Dr A. Howard: Management tips from a nail clinic  
| 1345   |                                               |                       |                   | Questions  
| 1355   |                                               |                       |                   | END OF SESSION  
| 1400   | **REGISTRARS’ AND FELLOW UPDATE SESSION 3**  | Parkside 2             | Dr. S. Zagarella  | A/Prof. S. Zagarella and Dr K. Chen: Evidenced based medicine lecture series  
|        |                                               |                       |                   | Mr. M. Barbic: Safety of medical records and medical communication  
|        |                                               |                       |                   | A/Prof. A. Oakley: Clinical photography in your dermatology practice  
|        |                                               |                       |                   | Dr. T. Blake: Desmoplastic trichoepithelioma - a case series and review of management  
|        |                                               |                       |                   | Dr P. Lowe: The lost art of compounding  
|        |                                               |                       |                   | Dr V. Tng: Dermatological manifestations of inflammatory bowel disease  
|        |                                               |                       |                   | Questions  
| 1515   |                                               |                       |                   | END OF SESSION  
| 1600-1700 | **REGISTRARS’ AND FELLOW UPDATE SESSION 4** | Parkside 2             | Dr. S. Zagarella  | Dr S. Fosko, Dr I. Hamann, Dr D. Lim and Dr E. Upjohn: Ask the experts’. Defects presented with panel discussing repair options  
|        |                                               |                       |                   | Dr R. Rosen and Dr T. Stewart: Surgical practices of Australian dermatologists  
|        |                                               |                       |                   | Dr C. Reddy: Nasal repairs, a plastic surgical perspective  
|        |                                               |                       |                   | Dr R. Cocciolone: Surgical pearls: Facilitating wound closure in fragile skin and a burrow’s free A to T advancement flap  
|        |                                               |                       |                   | Dr L.J. Leow: Diagrammatically simple but technically complex: Z-plasty, the nasolabial flap and the keystone flap  
|        |                                               |                       |                   | Questions  
| 1700   |                                               |                       |                   | END OF SESSION  
| 1730   |                                               |                       |                   | END OF SESSION  
| 1730   |                                               |                       |                   | END OF SESSION  

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1730-1830</td>
<td><strong>SPONSORED SYMPOSIUM</strong>&lt;br&gt;Room: Pyrmont Theatre&lt;br&gt;Chair: Prof. G. Varigos&lt;br&gt;A/Prof. P. Fernandez-Peñas and Dr J. Sullivan&lt;br&gt;IL-17 inhibition in psoriasis: Hard to treat psoriasis, quality of life aspects. This symposium will touch on two key topics with IL-17 inhibition in psoriasis. It reviews role of IL-17 inhibition in management of hard to treat psoriasis phenotypes. It also discusses the impact of severe psoriasis on QoL, touching on the relationship between PASI and QoL.</td>
</tr>
<tr>
<td>1730-1930</td>
<td><strong>MOHS SURGERY SESSION</strong>&lt;br&gt;Room: Meeting Rooms C2.2 and C2.3</td>
</tr>
</tbody>
</table>

**SOCIAL PROGRAM**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1930-2330</td>
<td><strong>CONFERENCE DINNER, PARKSIDE BALLROOM</strong>&lt;br&gt;International Convention Centre Sydney</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------------------------------</td>
</tr>
<tr>
<td>0800-1700</td>
<td>Registration Desk Open</td>
</tr>
<tr>
<td>0830-0845</td>
<td>Welcome to Country Opening by President Ms Y. Weldon, A/Prof. C. Baker</td>
</tr>
<tr>
<td>0845-1030</td>
<td>Session 1</td>
</tr>
<tr>
<td>0845</td>
<td>Ms S. Temby</td>
</tr>
<tr>
<td>0900</td>
<td>Dr S. Smithson</td>
</tr>
<tr>
<td>0930</td>
<td>Dr P. Artemi</td>
</tr>
<tr>
<td>1000</td>
<td>Dr S. Smith</td>
</tr>
<tr>
<td>1030</td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1030-1100</td>
<td>Morning Tea in the Trade Exhibition, Hall 1</td>
</tr>
<tr>
<td>1100-1230</td>
<td>Session 2</td>
</tr>
<tr>
<td>1100</td>
<td>Keynote Speaker - Ms L. Aldredge, RN</td>
</tr>
<tr>
<td>1200</td>
<td>C. Smith, RN</td>
</tr>
<tr>
<td>1230</td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1330-1430</td>
<td>Session 3</td>
</tr>
<tr>
<td>1330</td>
<td>Dr M. Hunt</td>
</tr>
<tr>
<td>1400</td>
<td>Mr P. Faga, RN</td>
</tr>
<tr>
<td>1430</td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1430-1500</td>
<td>Afternoon Tea in the Trade Exhibition, Hall 1</td>
</tr>
<tr>
<td>1500-1630</td>
<td>Session 4</td>
</tr>
<tr>
<td>1500</td>
<td>Dr M. Whitfeld</td>
</tr>
<tr>
<td>1530</td>
<td>Cl. A/Prof. S. van Nunen</td>
</tr>
<tr>
<td>1600</td>
<td>Ms M. Weaich, RN</td>
</tr>
<tr>
<td>1630</td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1900</td>
<td>EGO Dinner</td>
</tr>
</tbody>
</table>

**Demonstrated relief for your eczema patients**

**cetaphil.com.au**
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Chair</th>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
<tbody>
<tr>
<td>0730</td>
<td>Dr J-A. See</td>
<td>Pyrmont</td>
<td>Dr J-A. See</td>
<td>0730</td>
<td>Dr D. Maor</td>
<td>Parkside</td>
<td>A/Prof. R. Nixon</td>
</tr>
<tr>
<td>0731</td>
<td>Introduction</td>
<td>Theatre</td>
<td></td>
<td>0740</td>
<td>Dr P. Dickison</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0738</td>
<td>Dr J-A. See and A/Prof. M. Rademaker</td>
<td></td>
<td>Panel - question and answer</td>
<td>0747</td>
<td>Dr L. Ly</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0751</td>
<td>Dr J-A. See</td>
<td></td>
<td>What’s new for 2017</td>
<td>0759</td>
<td>Dr V. Harris</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0755</td>
<td>Prof. M. Nielsen</td>
<td></td>
<td>A new biophotonic treatment – explained!</td>
<td>0806</td>
<td>Dr D. Maor</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0800</td>
<td>Prof. R. Paus</td>
<td></td>
<td>Translational biology of the pilosebaceous unit re-visited: Relevance to acne and hidradenitis</td>
<td>0816</td>
<td>Dr D. Slope</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0830</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td>0823</td>
<td>Questions</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0845</td>
<td>Dr J. Sullivan, A/Prof. M. Rademaker and Dr M. Gupta</td>
<td></td>
<td>Introduction</td>
<td>0845</td>
<td>Dr M. Whitfeld</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0850</td>
<td>Dr P. Dickison</td>
<td></td>
<td>Characteristics of itch in psoriasis: The results from a dermatology clinic</td>
<td>0855</td>
<td>Dr J. Rhodes and Dr R. Saunderson</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0900</td>
<td>Prof. R. Sinclair</td>
<td></td>
<td>Tildrakizumab, a selective IL-23p19 antibody, in the treatment of chronic plaque psoriasis: Results from two randomised, controlled, phase 3 trials</td>
<td>0905</td>
<td>Dr M. Rodrigues</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0910</td>
<td>Dr A. Bhullar</td>
<td></td>
<td>The prevalence of synovitis and tenosynovitis in the small joints of the hands using ultrasonography in patients with chronic plaque psoriasis but undiagnosed psoriatic arthritis</td>
<td>0915</td>
<td>Dr L. Romani</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0920</td>
<td>A/Prof. M. Rademaker</td>
<td></td>
<td>Australasian psoriasis collaborative recommendations for methotrexate</td>
<td>0925</td>
<td>Dr T. O’Brien</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0933</td>
<td>Dr D. Rubel</td>
<td></td>
<td>Australasian psoriasis collaborative (APC) recommendations for managing malignancy in the psoriatic patient</td>
<td>0935</td>
<td>Dr N. Sharma</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>0946</td>
<td>Dr M. Andrews</td>
<td></td>
<td>Psoriasis in those planning a family, pregnant or breastfeeding. The Australasian psoriasis collaboration</td>
<td>0945</td>
<td>Dr M. Tuicakau</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td>Panel discussion</td>
<td></td>
<td></td>
<td>0955</td>
<td>Panel discussion</td>
<td>Parkside</td>
<td></td>
</tr>
<tr>
<td>1015</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td>1015</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>----------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1015-1100</td>
<td>MORNING TEA IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1100-1230</td>
<td>PLENARY SESSION 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room: Pyrmont Theatre</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Dr M. Gupta</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1100</td>
<td>Prof. A. Anstey</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phototherapy in eczema</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1120</td>
<td>Dr P. Dickison</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Serious games and innovative technology for dermatology education</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1130</td>
<td>Dr C. Scarff</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Why is it so hard to give negative feedback to underperforming specialist trainees?</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1140</td>
<td>Prof. R. Rapini</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mucinoses</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1155</td>
<td>Dr J. Frew</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Drug induced hidradenitis suppurativa / acne inversa: A systematic review of case reports with insights into pathogenesis of disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1205</td>
<td>Dr L. Ge</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A prospective 5-year Australian renal and liver organ transplant dermatology study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1215</td>
<td>Dr R. Kelly</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Livedo racemosa: The relationship between lymphocytic and neutrophilic vasculitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1225</td>
<td>Questions</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1230</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1230-1345</td>
<td>LUNCH IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1345-1515</td>
<td>CLINICOPATHOLOGICAL PATHOLOGICAL CORRELATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Room: Parkside 2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Dr K. Crotty and Dr G. Gottschalk</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>11 interesting cases to be presented and discussed with lots of audience participation!</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1515</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1515-1600</td>
<td>AFTERNOON TEA IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0800-1500</td>
<td>REGISTRATION DESK OPEN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0900-1030</td>
<td>SESSION 5</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rooms: Meeting Rooms C2.2 and C2.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0900</td>
<td>Dr E. Dawes-Higgs</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Female genital dermatology: A brief introduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0930</td>
<td>Annual General Meeting</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1000</td>
<td>Dr L. Sagi</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Interesting psoriasis case studies</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1030</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1030-1100</td>
<td>MORNING TEA IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1100-1200</td>
<td>SESSION 6</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rooms: Meeting Rooms C2.2 and C2.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1100</td>
<td>Ms L. Aldredge, RN</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Psoriasis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1130</td>
<td>A/Prof. G. Fischer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paediatric conditions that mimic abuse</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1200</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1200-1300</td>
<td>LUNCH IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1300-1515</td>
<td>SESSION 7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rooms: Meeting Rooms C2.2 and C2.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1300</td>
<td>A/Prof. M. Schifter</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Oral dermatology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1400</td>
<td>BDNG Representative</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Updates in British dermatology nursing</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1430</td>
<td>Dr S. Donoghue</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Weird and wonderful</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1500</td>
<td>Ms S. Temby</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Award presentations and member’s draw</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1515</td>
<td>END OF SESSION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CEREMONY FOR CONFERRING OF DIPLOMAS AND AWARDS ON THE OCCASION OF THE 50TH ANNIVERSARY OF THE AUSTRALASIAN COLLEGE OF DERMATOLOGISTS

Sunday 7 May 2017, 5.00pm
The Great Hall,
The University of Sydney,
Science Road,
Camperdown NSW 2050

PROGRAM

PROCESSIONAL MUSIC
Trumpet Voluntary

ACADEMIC PROCESSION
The audience is requested to stand when the academic procession enters the hall; and to remain standing for the singing of the National Anthems of Australia and New Zealand.

OPENING PROCEEDINGS
Associate Professor Chris Baker, President of the Australasian College of Dermatologists, will declare the proceedings open and address the assembly.

BELISARIO AWARD FOR ACADEMIC DERMATOLOGY
Professor Gary Halliday

SILVER MEDAL
Dr James Butler AM
Associate Professor Rosemary Nixon
Associate Professor Stephen Shumack OAM
Dr John Sippe

CERTIFICATE OF MERITORIOUS SERVICE
Dr Pamela Brown
Dr Judith Cole
Dr David Cook
Dr Alan Donnelly
Dr Timothy Elliott
Associate Professor Gregory Goodman
Dr Jeremy Horton
Dr Gillian Marshman
Dr Jennifer Menz
Dr Catherine Reid
Dr Michael Rich
Dr Ivan Robertson
Clinical Associate Professor Duncan Stanford

HONORARY FELLOW
Professor Jean Bolognia
Professor John Hawk
Professor John McGrath

INTERNATIONAL OUTREACH AWARD
Dr Timothy O’Brien

MERYN GOLD, OAM, AWARD
Dr Neville Collins
Dr Ian McCrossin

CERTIFICATE OF SERVICE
Dr Bob Corderoy
Mr Tony Moore

GRADUATE FROM THE ACD MOHS MICROGRAPHIC SURGERY TRAINING PROGRAM
Dr Peggy Chen
Dr Douglas Coates

FELLOWS ELECTED UNDER CLAUSE 3.2 OF THE COLLEGE CONSTITUTION
Dr Mark Darling
Dr Lior Sagi
Professor Werner Sinclair
Dr Ritva Vyas
Dr Ebrahim A K Abdulla

INDUCTION OF NEW FELLOWS
Dr Austen Anderson
Dr Friyana Bhabha
Dr Melissa Carroll
Dr Mark Cicchiello
Dr John Frew
Dr Daniel Gaffney
Dr Dallas Gramp
Dr Amy Kline
Dr Lena Ly
Dr Georgina Lyons
Dr Emma Mooney
Dr Rebecca Nguyen
Dr Christopher Ross
Dr Salvatore Scuderi
Dr Deshan Sebaratnam
Dr Devita Surjana
Dr Bonnie Swan
Dr Matthew Warren
Dr Annaliesa Wright

AUSTRALASIAN COLLEGE OF DERMATOLOGISTS TRAVELLING FELLOWSHIP FROM 2016
EXAMINATIONS AND KEN PATER MEDAL FOR MEDICAL DERMATOLOGY FOR 2016
Dr Georgina Lyons

FOUNDERS’ MEDAL FOR PROCEDURAL DERMATOLOGY FOR 2016
Dr Rebecca Nguyen

PRESIDENT'S MEDAL FOR PHARMACOLOGY FOR 2016
Dr Sarah Smithson

ADRIAN JOHNSON MEMORIAL PRIZE FOR 2016
Dr Casey Rowe

EILEEN COLLINS MEMORIAL PRIZE FOR 2016
Dr Andrew Lee

OATH OF ETHICS
The new Fellows will affirm the Oath of Ethics.

The Oath will be recited by Dr Georgina Lyons.

MUSIC INTERLUDE
Battle Suite

JOHN REID ORATION
To be given by The Honourable Michael Kirby AC CMG

CONCLUSION
The assembly is requested to stand as the academic procession leaves the auditorium.

RECESSIONAL MUSIC
Trumpet Tune

MUSIC
Modest Brass

CARILLONIST/ORGANIST
Amy Johansen

GUESTS OF HONOUR
His Excellency General The Honourable David Hurley AC DSC (Ret’d), Governor of New South Wales and Mrs Linda Hurley

Guests of the conferring ceremony are invited to stay and enjoy light refreshments in the MacLaurin Hall.

Buses will depart regularly from the University starting at 1900 (returning to the ICC Sydney). Last bus departs at 2015.
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Room</th>
<th>Chair</th>
</tr>
</thead>
</table>
| 0730-0830 | **GENITAL DERMATOLOGY**  
Room: Pyrmont Theatre  
Chairs: Dr C. Drummond and Dr I. McCrossin | 0730 | Dr K. Deen  
Imiquimod in the treatment of penile intraepithelial neoplasia: An update |
|        |                                 | 0739 | Dr E. Dawes-Higgs  
An update on the classification of vulval squamous intraepithelial lesions |
|        |                                 | 0746 | Dr V. Harris  
Development and validation of vulval disease quality of life index (VDQLI) |
|        |                                 | 0753 | Dr Y. Nguyen  
The association between chronic vulvovaginal candidiasis and use of the levonorgestrel-releasing intrauterine system |
|        |                                 | 0800 | A/Prof. A. Hall and A/Prof. G. Fischer  
Female and male genital dermatology - all you need to know |
|        |                                 | 0830 | END OF SESSION |
| 0830-1015 | **MEDICAL DERMATOLOGY**  
UPDATE  
Room: Pyrmont Theatre  
Chair: Dr H. Fallah | 0845 | Prof. A. Anstey  
Publication ethics |
|        |                                 | 0900 | Prof. R. Sinclair  
Treatment of chronic telogen effluvium with oral minoxidil |
|        |                                 | 0910 | Dr A. Saracino  
Systemic sclerosis and morphea: Role of a dermatologist |
|        |                                 | 0920 | Dr R. Rosen  
Review of 10 year data of axillary hyperhidrosis therapy |
|        |                                 | 0930 | Dr D. Rubel  
Biologics beyond psoriasis |
|        |                                 | 0940 | Dr A. Gin  
The classification and diagnostic algorithm for primary lymphatic dysplasia: An update for 2017 |
|        |                                 | 0950 | Dr T. Papps  
Contribution to medical dermatology – the Australian cutaneous lymphoma multidisciplinary team |
|        |                                 | 1000 | Questions |
|        |                                 | 1015 | END OF SESSION |
| 1015-1100 | **PAEDIATRIC DERMATOLOGY**  
Room: Parkside 2  
Chair: Dr L-C. Wong | 0730 | A/Prof. G. Fischer  
The management of paediatric vulval conditions |
|        |                                 | 0740 | Dr A. Halbert  
Update on the use of topical and oral sirolimus in paediatric dermatology |
|        |                                 | 0750 | Dr P. Hogan  
What I have learned - paediatric dermatology pearls |
|        |                                 | 0800 | Dr L. Warren  
Update - infestations and dermatophytes |
|        |                                 | 0810 | Dr D. Orchard  
Update in the topical management of ichthyoses |
|        |                                 | 0820 | Dr O. Wargon  
Clinical spectrum of CM-AVM syndrome |
|        |                                 | 0830 | END OF SESSION |
| 1100-1200 | **ART OF DERMATOLOGY AND OTHER SURPRISES**  
Room: Parkside 2  
Chair: Dr P. Brown | 0845 | Dr T. O’Brien  
Painting the skin |
|        |                                 | 0900 | A/Prof. S. Kossard  
Dermatopathology and abstract art photography |
|        |                                 | 0915 | Cl. A/Prof. C. Commens  
Ethics and dermatology. Lessons learned |
|        |                                 | 0930 | Dr M. Lane-Brown  
The art of dermatology |
|        |                                 | 0945 | Dr C. Quirk  
The art of dermatology: Satisfactory outcomes |
|        |                                 | 1000 | Dr P. Brown  
Therapy is a partnership |
<p>|        |                                 | 1015 | END OF SESSION |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>1100-1230</td>
<td>PLENARY 3</td>
<td>Prof. R. Rapini</td>
<td>Rare infections</td>
</tr>
<tr>
<td>1100</td>
<td></td>
<td>Dr I. McCrossin</td>
<td>Strongyloides in Australia - please don’t kill the patient</td>
</tr>
<tr>
<td>1125</td>
<td></td>
<td>Dr S. Rea</td>
<td>The 2015-2016 syphilis outbreak of far North Queensland</td>
</tr>
<tr>
<td>1135</td>
<td></td>
<td>Dr N. Adler</td>
<td>Nosocomial crusted scabies outbreaks at an Australian tertiary hospital: Infection prevention lessons learned from a small case series</td>
</tr>
<tr>
<td>1145</td>
<td></td>
<td>Dr A. Laino</td>
<td>Systematic review of literature for treatment of chromoblastomycosis</td>
</tr>
<tr>
<td>1155</td>
<td></td>
<td>Dr A. Lara Rivero</td>
<td>Tropical dermatoses not gone but forgotten?</td>
</tr>
<tr>
<td>1205</td>
<td></td>
<td>Dr A. Yazdabadi</td>
<td>Cutaneous leishmaniasis, pearls from Persia</td>
</tr>
<tr>
<td>1215</td>
<td></td>
<td></td>
<td>Questions</td>
</tr>
<tr>
<td>1230</td>
<td></td>
<td></td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1230-1345</td>
<td>LUNCH IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1345-1515</td>
<td>PROFESSIONALISM AND ETHICS CONGRESS 1</td>
<td>Dr W. Lipworth</td>
<td>Ethics in medicine</td>
</tr>
<tr>
<td>1345</td>
<td></td>
<td>Dr J. Jureidini</td>
<td>Medical research: Selective reporting, publication bias, citation distortion, ghostwriting and endemic failure in pharmacovigilance</td>
</tr>
<tr>
<td>1405</td>
<td></td>
<td>Prof. L. Bero</td>
<td>Big pharma. What have we learned from pharmaceutical industry documents?</td>
</tr>
<tr>
<td>1425</td>
<td></td>
<td>Dr B. Mintzes</td>
<td>Who’s taking dermatologists out to dinner?</td>
</tr>
<tr>
<td>1505</td>
<td></td>
<td></td>
<td>Questions</td>
</tr>
<tr>
<td>1515</td>
<td></td>
<td></td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1515-1600</td>
<td>AFTERNOON TEA IN THE TRADE EXHIBITION, HALL 1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Speaker(s)</td>
<td>Details</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
<tr>
<td>1600-1645</td>
<td>PROFESSIONALISM AND ETHICS CONGRESS 2</td>
<td>A/Prof. S. Zagarella</td>
<td>A/Prof. S. Zagarella presented on Conflicts of interest in medical journals.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mr. T. Wills</td>
<td>Mr. T. Wills presented on Ethics talk.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1624 - Debate</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1636 - Questions</td>
</tr>
<tr>
<td>1645-1730</td>
<td>ANNUAL GENERAL MEETING</td>
<td></td>
<td>Annual General Meeting presented for Fellows and Associate Members of the College only.</td>
</tr>
<tr>
<td>1730</td>
<td></td>
<td></td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1730-1830</td>
<td>SPONSORED SYMPOSIUM</td>
<td>Dr. A. Egeberg and Dr C-H. Hong</td>
<td>Dr. A. Egeberg and Dr C-H. Hong presented on Setting clear objectives for psoriasis treatment: Use of ixekizumab in clinical practice. This symposium will focus on the clinical efficacy and safety of ixekizumab in moderate-to-severe plaques psoriasis, specifically in challenging situations. Dr Egeberg from Denmark and Dr Hong from Canada will present case-based scenarios and lead an interactive discussion forum on each case.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1830</td>
<td></td>
<td></td>
<td>END OF SESSION</td>
</tr>
<tr>
<td>1600-1730</td>
<td>REGISTRAR TEACHING SESSION</td>
<td>Dr. S. Fosko</td>
<td>Dr. S. Fosko presented on Lentigo maligna: Observations, challenges and advances.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Dr. A. Marghoob</td>
<td>Dr. A. Marghoob presented on TADA: Dermoscopy simplified.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof. R. Rapini</td>
<td>Prof. R. Rapini presented on Journey in dermatology.</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prof. A. Anstey</td>
<td>Prof. A. Anstey presented on How to get published.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>1730 - END OF SESSION</td>
</tr>
<tr>
<td>1730-1830</td>
<td>SPONSORED SYMPOSIUM</td>
<td>A/Prof. S. Smith and Dr J. Streimer</td>
<td>A/Prof. S. Smith and Dr J. Streimer presented on The new normal – patient anxiety regarding treatment success. We are all aware patients are anxious their psoriasis treatment may not work as well as they expect. But what about the issues they may face when it does? And how does this, and the fear their new treatment may stop working, affect their efforts to cope with this New Normal? Join us to discuss the psychological impact of psoriasis and management of patients with anxiety during their treatment journey.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>END OF SESSION</td>
</tr>
</tbody>
</table>
### Registration Desk Open

| 0730-0830 | Registrars’ Forum  
Room: Pyrmont Theatre  
Chair: Dr A. Lim |
|-----------|-------------------------------------------------|
| 0730 | Dr F. Poon  
Impact of neck lymphadenectomy on head and neck cutaneous melanoma recurrence and survival: A 10 year retrospective study |
| 0737 | Dr V. Tng  
General practice trainees’ clinical exposure to dermatological procedures during training: An analysis from the registrar clinical encounters in training study |
| 0744 | Dr J. Kim  
Can neutrophilic eccrine hidradenitis be part of azathioprine hypersensitivity syndrome? |
| 0751 | Dr B. Choy  
Is the AQLQ-8D a more sensitive instrument than the skindex-16 for measuring impact of skin conditions on quality of life? |
| 0758 | Dr P. Banan  
Morbihan’s disease in a patient with skin type IV and challenges of treatment |
| 0805 | Dr R. Anforth  
Treatment of disseminated actinic porokeratosis |
| 0812 | Dr J. Elakis  
Skin disease of penis and male genitalia is linked to atopy and circumcision: Aselod in a male genital dermatology clinic |
| 0819 | Dr L. Pitney  
Patch testing for cutaneous adverse drug reactions |
| 0826 | Questions |
| 0830 | END OF SESSION |

### Non-melanoma Skin Cancer Symposium

| 0845-1015 | Non-melanoma Skin Cancer Symposium  
Room: Pyrmont Theatre  
Chair: Dr I. Hamann |
|-----------|-----------------------------------------------------------------|
| 0845 | Dr S. Fosko  
Targeted therapy and cutaneous squamous cell carcinoma |
| 0855 | Prof. M. Veness  
Update on merkel cell carcinoma |
| 0905 | Prof. M. Veness  
Sentinel lymph node biopsy in high risk SCC |
| 0915 | Dr B. Yau  
Atypical fibroxanthoma/pleomorphic dermal sarcoma at the Peter MacCallum Cancer Centre 2002-2016 |
| 0925 | Dr R. Minocha  
Nicotinamide for skin cancer chemoprevention: Effects on tumour immune infiltrates and melanoma biology |
| 0935 | A/Prof. P. Foley  
Structured expert consensus on actinic keratosis: An up-to-date treatment algorithm |
| 0945 | A/Prof. C. Palme  
Update on the surgical management of head and neck perineural invasion |
| 0955 | Dr X. Yang  
Triple hedgehog pathway inhibition for advanced basal cell carcinoma |
| 1005 | Questions |
| 1015 | END OF SESSION |

### Dermatology Hospitalists

| 0730-0830 | Dermatology Hospitalists  
Room: Parkside 2  
Chair: A/Prof. P. Fernandez-Penas |
|-----------|-----------------------------------------------------------------|
| 0730 | A/Prof. P. Fernandez-Penas  
Presentation of dermatology hospitalists |
| 0731 | Dr N. Adler  
Recent advances in the understanding and management of severe cutaneous adverse reactions |
| 0745 | Dr G. Marshman  
Rheumatology/dermatology MDT |
| 0755 | Dr J. Wells  
Update in cutaneous lymphomas |
| 0805 | A/Prof. G. Cains  
Managing hidradenitis suppurativa in a hospital MDT |
| 0815 | Questions |
| 0830 | END OF SESSION |

### Cosmetic Dermatology for General Dermatologists

| 0845-1015 | Cosmetic Dermatology for General Dermatologists  
Room: Parkside 2  
Chair: Dr M. Hunt |
|-----------|-----------------------------------------------------------------|
| 0845 | Dr M. Hunt  
A 3-D approach to facial ageing |
| 0855 | A/Prof. M. Freeman  
Ameliorating pigmentation and telangiectasia in the skin |
| 0905 | Dr A. Patel  
Levels of resurfacing |
| 0915 | Dr E. Dawes-Higgs  
Dermal fillers |
| 0925 | Dr A. Lim  
High-speed low-pain micro-focused ultrasound tightening of the lower face and neck |
| 0935 | Dr N. Wines  
Botulinum toxin |
| 0945 | Dr P. Sharma  
Hair transplantation surgery: Where are we now? |
| 0955 | Dr P. Artemi  
Cosmeceutical options in dermatology practice |
| 1005 | Dr M. Hunt  
Beyond skin deep |
| 1010 | Questions |
| 1015 | END OF SESSION |
### MORNING TEA IN THE TRADE EXHIBITION, HALL 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1015-1100 | PLENARY 4 AND AWARDING OF PRIZES  
Room: Pyrmont Theatre  
Chair: Dr A. Miller |

**1100**  
Dr A. Marghoob  
How effective is dermoscopy in the early detection of melanoma?

**1120**  
Prof. M. Ziman  
Liquid biopsies for diagnosis and prognosis of melanoma

**1130**  
Dr D. Chung  
Ultrasound monitoring of lymph node metastasis in melanoma

**1140**  
Dr P. Star  
Defining lentigo maligna and its margins and identifying predictors of recurrence: Correlation of clinical, dermatoscopic, confocal microscopy and histopathological data

**1150**  
Dr S.J.E. Hwang  
Cutaneous adverse reactions to immunotherapies for metastatic melanoma

**1200**  
Dr N. Maher  
Desmoplastic melanoma: A diagnostic difficulty

**1210**  
Prof. D. Damian  
DPCP in the age of systemic immunotherapy

**1220**  
Awarding of prizes

**1230**  
END OF SESSION

### LUNCH IN THE TRADE EXHIBITION, HALL 1

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1345-1515 | WHAT'S NEW IN JOURNALS  
Room: Pyrmont Theatre  
Chair: Dr K. Chen |

**1345**  
Dr H. Fallah  
What's new in medical dermatology

**1405**  
Dr S. Lee  
What's new in surgical dermatology

**1425**  
Dr K. Crotty  
What's new in dermatopathology

**1445**  
Dr L-C. Wong  
What's new in paediatric dermatology

**1505**  
Questions

**1515**  
END OF SESSION

### FREE PAPERS

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1345  | Prof. D. Murrell  
Contributions of the independent learning program at University of New South Wales to dermatology registrar training 2006-2016 |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1355  | Prof. G. Varigos  
50 years ACD are we closer to a vaccine for psoriasis? |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1405  | Prof. N. Haass  
Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1425  | Prof. N. Haass  
Cell cycle-tailored targeting of metastatic melanoma: Challenges and opportunities |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1435  | Dr P. Guitera  
Blue-grey pigmented lesions on trauma sites |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1455  | Dr L. Abbott  
Surveillance by smartphone: Can a patient record a consultation without your consent? |

### SOCIAL PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1130  | GOLF TOURNAMENT  
The Lakes Golf Club  
Corner King Street and Vernon Avenue, Eastlakes  
Please arrive at 1130 for a 1220 tee off. |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1505  | Dr C. Gollins  
A study of the number of female editors-in-chief of dermatology journals |

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1515</td>
<td>Questions</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1515</td>
<td>END OF SESSION</td>
</tr>
</tbody>
</table>
POSTER PRESENTATIONS

This year the posters will be displayed electronically in the ASM central feature in the trade exhibition. Posters can be viewed individually on computer terminals or delegates may access the e-Posters on their own device via the link http://acd2017asm.paperlessevents.com.au/
The link is also available in the menu bar of the ASM app.

1. Dr L. Abdel-Malek
   Dermatology conferences and societies represented on postage stamps
2. Dr L. Abdel-Malek
   Flagellate mushroom dermatitis: An uncommon emergency presentation
3. Dr L. Abdel-Malek
   Postage stamps and dermatology: Recognition of the dermatologist
4. Dr A. Adams
   Incidental perineural invasion in NMSC: A retrospective analysis of the QSkin study and a five year follow up in Queensland.
5. Dr A. Adams
   Nine primary melanomas in a young female patient and a review of the literature
6. Dr N. Adler
   A novel clinical sign to aid in the diagnosis of superficial basal cell carcinoma
7. Dr N. Adler
   Clinical and molecular characteristics and metastatic pathways in patients with cutaneous melanoma
8. Dr N. Adler
   Cutaneous adverse drug reactions and drug-induced liver injury: A retrospective cohort study
9. Dr N. Adler
   Successful treatment of pemphigus vulgaris with rituximab in a patient with severe vulvar involvement
10. Dr N. Adler
    Treatment of pemphigus vegetans with rituximab: A case report and review of the literature
11. Dr E. Anthony
    Acute generalised pustular psoriasis of pregnancy
12. Dr E. Anthony
    Pemphigus vulgaris: Therapeutic approach
13. Dr C. Barker
    Secukinumab treatment shows no evidence of increased mycobacterium tuberculosis infections: Findings from in vitro, in vivo and clinical investigations
14. Dr T. Barrett
    Minocycline induced hyperpigmentation. A comparison of Q-Switched Nd:YAG laser and picosecond alexandrite laser
15. Dr R. Barsoum
    Relationship between melanocytic naevi (MN) acquired during childhood and adult MN count and melanoma risk
16. Dr K. Beem
    A case of dermal non-necrotising granulomatous disease
17. Dr K. Beem
    Case series: Tinea incognito
18. Ms G. Bellemere
    A multidisciplinary approach of neonate and newborn hygiene and skin care
19. Ms G. Bellemere
    A natural cosmetic active ingredient dedicated to the needs of pregnant woman’s skin
20. Ms G. Bellemere
    Characterisation of dry skin in vitro and in vivo in a paediatric population
21. Ms G. Bellemere
    Diaper dermatitis management: A global and innovative strategy for a new generation of skin care
22. Ms G. Bellemere
    Improving stretch mark pathophysiology knowledge by specific in vitro models
23. Ms G. Bellemere
    In vitro models of infant skin to study molecular mechanisms involved in paediatric atopic dermatitis
24. Ms G. Bellemere
    In vivo and in vitro demonstration of efficacy of specific skin care products for normal and dry baby skin
25. Ms G. Bellemere
    Objective assessment of roughness of dry skin in a pediatric population
26. Ms G. Bellemere
    Studying the role of S. aureus and its biofilm in atopic dermatitis pathogenesis using in vitro 3D models
27. Dr A. Bhullar
    A cross-sectional multicentre study to assess the quality of life in leprosy patients
28. Dr T. Blake
    Desmoplastic trichoepithelioma - large case series, clinicopathology and management review
29. Dr T. Blake
    Updating dermatology medicine ingredient names in Australia – it’s happening right now!
30. Dr A. Blauvelt
    Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: Results from the phase 3-VOYAGE 1 study
31. Dr S. Bodapati
    Erythema nodosum and granulomatous mastitis: Case study and discussion
32. Dr L. Buchanan
    A rare case of drug induced cutaneous lupus with tocilizumab for rheumatoid arthritis
33. Dr J. Bu
    Acute graft-versus-host-disease mimicking EAC: An atypical cutaneous presentation
34. Dr J. Bu
    Escherichia coli septicaemia induced purpura fulminans
35. Dr J. Bu
    Malignant melanoma and men’s health: The unspoken link
36. Dr J. Bu
    Topical glyceryl trinitrate treatment in chronic radiation dermatitis
37. Dr N. Burkhardt
    Absolute and relative PASI over 1 year of treatment with ixekizumab (IXE): Descriptive analysis in patients with moderate-to-severe plaque psoriasis
38. Dr N. Burkhardt
Efficacy and safety of ixekizumab (IXE) compared to ustekinumab (UST) in patients with moderate-to-severe plaque psoriasis: A randomised head-to-head trial

39. Dr N. Burkhardt
Indirect comparison of ixekizumab (IXE) and secukinumab (SEC) using matched-adjusted indirect comparisons (MAIC)

40. Dr N. Burkhardt
Ixekizumab (IXE) treatment enables rapid improvements in health-related quality of life (HRQoL) and itch: Results from UNCOVER-2 and UNCOVER-3

41. Dr M.A. Castrillon
A case report of lupus erythematosus profundus

42. Dr J. Cather
≥156-week apremilast safety and tolerability in patients with moderate to severe psoriasis and cardiometabolic comorbidities: ESTEEM pooled analysis

43. Dr K. Chakradeo
Atypical cellulitis in transplant recipients: A case report and review of the literature

44. Dr K. Chakradeo
Eruptive seborrheic keratoses in a patient with intra-abdominal malignancy: Sign of leser–trélat

45. Dr M.Y.L. Chan
Muscle, skin or both? Concurrent psoriasis and dermatomyositis with pembrolizumab treatment of metastatic melanoma

46. Dr M.Y.L. Chan
Red and sore in a rare patient

47. Dr S-L. Chan
A case of bullous pemphigoid in a young adult

48. Miss S. Chap
Profiling cysteine protease activity in atopic dermatitis

49. Miss S. Chap
Treatment of cutaneous kaposi sarcoma with topical timolol

50. Dr O. Charlton
Leprosy: An ancient disease that still threatens global health

51. Dr H.M. Cheng
Prospective review of lichen planus pigmentosus (LPP) and ashy dermatosis (AD) – Risk factors, clinicopathologic features, and treatment outcomes

52. Dr M. Cho
Plantar keratoderma associated with developmental delay, intellectual impairment and abnormal facial features. A possible new gene (FOXPI) association

53. Dr H. Collgros
In vivo reflectance confocal microscopy on the lip: From normal to sun damaged skin and non-melanocytic skin cancer

54. Miss C. Cox
Efficacy of home-based chemo-wraps of topical 5-fluorouracil for disseminated superficial actinic porokeratosis compared to ablative erbium laser: Comparative case study

55. Dr W. Cranwell
The role of sunscreen and facial skin care products in frontal fibrosing alopecia

56. Dr J. Crowley
≥156-week apremilast safety in psoriasis and psoriatic arthritis patients: Pooled analysis of the ESTEEM and PALACE phase 3 trials

57. Dr K. Darch
Investigating the correlation between ion channels and receptors that detect irritants, and itchy, inflammatory skin conditions
58. Dr J. Davey
Life on the beach: The knowledge, behaviours and attitudes of Australian surf lifesavers towards sun protection

59. Dr S. Dawood
The U.K. skin cancer ‘two-week rule’ referral system: Audit to ascertain appropriate referrals at our institution

60. Dr N. De Rosa
Dermatological disease in heart and lung transplant recipients: A cross-sectional and prospective study

61. Dr N. De Rosa
Skin cancer incidence and risk factors in Australian heart and lung transplant recipients: A single-centre retrospective study

62. Dr J. Deen
Extrafacial granuloma faciale

63. Dr J. Deen
Severe, malignant acanthosis nigricans associated with adenocarcinoma of the endometrium

64. Dr P. Dickison
Cardiovascular risk in psoriasis patients

65. Dr P. Dickison
Medical student perceptions of dermatology teaching: A focus group study

66. Dr P. Dickison
Professional perceptions of dermatology teaching: A focus group study

67. Dr P. Dickison
Psoriasis patients’ knowledge of comorbidities

68. Dr B. Doolan
Management of primary cutaneous melanoma: A retrospective audit of 349 cases and literature review of current clinical guidelines

69. Dr B. Doolan
Tinea capitis caused by trichophyton tonsurans in tropical Africa: A review of the scientific literature

70. Dr J. Elakis
Barriers to JMO participation in pressure injury prevention and management

71. Dr G. Farrah
A case of disseminated granuloma annulare associated with dermatomyositis

72. Dr L. Farrugia
Evaluation of the influence of family and friends, and the internet on patient perceptions of long-term topical corticosteroid use

73. A/Prof. P. Foley
Dupilumab with concomitant topical corticosteroids in moderate-to-severe atopic dermatitis: A randomised, placebo-controlled phase 3 clinical trial (CHRONOS)

74. A/Prof. P. Foley
Secukinumab shows significant efficacy in difficult-to-treat palmoplantar psoriasis: 1.5 year data from the GESTURE study

75. Dr J. Frew
A systematic review and critical evaluation of reported sequence variants in hidradenitis suppurativa/acne inversa using ACMG standards and guidelines

76. Dr S. Gabizon
Pyogenic granuloma like kaposi sarcoma

77. Dr L. Ge
A case of anhidrosis and widespread vitiligo-like depigmentation with metastatic melanoma immunotherapy

78. Dr A. Gin
Coxsackievirus A6 associated with eczema exacerbation in children

79. Cl. Prof. C-L. Goh
Management of post-acne scars in Asians - need for a paradigm shift?

80. Dr C. Gollins
A case of bladder calculi in non-herlitz junctional epidermolysis bullosa

81. Dr A. Gottlieb
Clinical response and minimal disease activity with the physician global assessment and body surface area tool: Apremilast ESTEEM analysis

82. Dr S. Hall
Secukinumab provides sustained improvement in psoriatic arthritis in both anti-TNF-naïve and anti-TNF exposed patients

83. Dr M. Hamid
Calcinphylaxis: Clinical presentation, causes and treatment, with case series

84. Dr M. Hamid
The evolution and workflow of the Princess Alexandra Hospitals’ teledermatology service, and an interesting case series

85. Ms E. Hao
Systematic review of neonatal cutaneous langerhan cell histiocytosis and metaanalysis of risk of progression to systemic disease

86. Dr V. Harris
Assessment of sun-protective attitudes and behaviours of parents and the impact on their children

87. Dr V. Harris
First case report of ustekinumab and botulinum toxin A injections in a patient

88. Dr V. Harris
Update: Autoimmune side effects of ipilimumab and pembrolizumab in metastatic melanoma. Case study of patient with hypophysitis, pneumonitis, colitis, vitiligo

89. Dr N. Huang
A case of granulomatosus cheilitis in miescher-melkerson-rosenthal syndrome

90. Dr S.J.E. Hwang
Cutaneous toxicities of anti-programmed death (anti-PD-1) antibodies in patients with advanced solid organ tumours

91. Dr S.J.E. Hwang
Difference in skin toxicities observed in patients with metastatic melanoma treated with combined pembrolizumab and ipilimumab vs pembrolizumab alone

92. Ms E. Janz-Robinson
Is it really vitiligo?

93. Dr T. Jeffery
Lichenified papules – an unusual cutaneous presentation of metastatic breast cancer

94. Dr H. Jibreal
Fractionated laser and radiofrequency treatments combined with low-dose isotretinoin for the concurrent treatment of active acne and acne scarring

95. Dr J. Johnston
A case of adult onset linear scleroderma, en coup de sabre variant responsive to methotrexate monotherapy: A review of treatment options
96. Dr J. Johnston
The correlation of sebaceous hyperplasia and colonic polyposis: An observational study

97. Dr P.S. Jones
Vitiligo surgery: A faster method of suction blistering using the celluTome device

98. Dr P. Kadam
Hydroxyurea induced squamous dysplasia

99. Dr P. Kadam
Systemic cutaneous anaplastic large t-cell lymphoma

100. Dr J. Kim
Multiple glomus tumours: A rare dermatological presentation

101. Dr M. Kim
Sirolimus-associated scrotal lymphedema and secondary development of lymphangiomatosis: Successful treatment with shave excision and cauterization

102. Dr J. Korbl
"Why don’t they ever call?: Critical diagnoses in dermatopathology

103. Miss E. KoZera
Patient and practitioner satisfaction with tele-dermatology including Australia’s indigenous population

104. Dr N. Laidler
Acute autoimmune hepatitis secondary to ipilimumab in metastatic melanoma

105. Dr A. Laino
Cutaneous adverse reactions following alemtuzumab therapy for multiple sclerosis

106. Dr A. Lee
Successful use of ibrutinib to control paraneoplastic pemphigus in a patient with paraneoplastic autoimmune multiorgan syndrome and chronic lymphocytic leukaemia

107. Dr S. Lee
Recalcitrant ulcers associated with SAE-positive dermatomyositis treated with surgery followed by intravenous immunoglobulin

108. Dr N. Ling
Granulomatous mycosis fungoides: A difficult diagnosis

109. Dr R. Liu
Nivolumab induced subacute cutaneous lupus erythematosus

110. Dr H. Lolatgis
Direct and indirect costs of adult atopic dermatitis in an inpatient and outpatient setting

111. Dr D. Maor
A case of acquired epidermodysplasia verruciformis in a renal transplant recipient clearing with multimodal treatment including gardasil vaccination

112. Dr D. Maor
Melanoma in a cohort of organ transplant recipients: Experience from a dedicated transplant dermatology clinic in Victoria

113. Dr D. Maor
Recalcitrant hyperkeratotic warts in a renal transplant recipient clearing with cessation of immunosuppression

114. Dr N. Martin
EASI-75 interpretation from a patient perspective – a phase 2b post-hoc analysis of dupilumab in adults with moderate-to-severe atopic dermatitis

115. Mr E. Mate
Secukinumab demonstrates sustained high efficacy and a tolerable safety profile in moderate-to-severe psoriasis patients through 4 years of treatment

116. Mr E. Mate
Secukinumab is efficacious in clearing moderate-to-severe scalp psoriasis: 12 week results of a randomised phase IIb study

117. Dr P. McDonald
A paradoxical reaction in a mycobacterium ulcerans infection

118. Dr R. Meani
Incidence of vulval squamous cell carcinoma in women with vulval lichen sclerosus in an Australian tertiary referral centre

119. Dr A. Mulcahy
A curious case of bed bugs and a lesson of referral caution

120. Dr A. Mulcahy
Dermatological conditions in haematology patients: Data from combined haematology/dermatology clinic

121. Dr A. Mulcahy
Suggested skin cancer screening protocol for chronic lymphocytic leukaemia patients

122. Prof. D. Murrell
A pilot study of the efficacy of a bruton’s tyrosine kinase inhibitor in the treatment of dogs with pemphigus foliaceus

123. Dr N. Nagodavithana
Nation wide survey on the use of photodynamic therapy among Australian dermatologists

124. Dr P. Nash
Secukinumab provides rapid and sustained reductions in dactylitis, enthesitis, and nail psoriasis in patients with psoriatic arthritis (PsA)

125. Dr Y. Nguyen
A case of cutaneous malakoplakia in a patient with chronic graft-versus-host disease

126. Dr Y. Nguyen
A case series of 16 patients with oestrogen hypersensitivity vulvitis treated with cyproterone acetate

127. Dr Y. Nguyen
Management of chronic vulvovaginal candidiasis: A long term retrospective study

128. Dr Y. Nguyen
Poor quality of life in patients with chronic vulvovaginal candidiasis: A before-after study on the impact of oral fluconazole therapy

129. Mr K. Nørremark
Innovation in delivery of a topical combination treatment (enstilar®) for psoriasis vulgaris

130. Dr D. Norris
Biologics and dermatology life quality index (DLQI) in the Australasian psoriasis population

131. Dr P. Peters
Combined dermatology/stomal clinic: A new multidisciplinary clinic

132. Dr C. Pham
Granular parakeratosis in adult female secondary to exposure of benzalkonium chloride laundry rinse

133. Dr V. Pilcher
The development of generalised granuloma annulare during treatment for palmoplantar psoriasis with ustekinumab
134. Dr V. Pilcher
The development of vitiligo while receiving ustekinumab therapy for chronic plaque psoriasis - a case series

135. Dr M. Robinson
Large brown scale: DDx and Ix. A case report of X-linked ichthyosis and review of literature on treatment options

136. Dr R. Sauderson
Teledermatology – how accurate is it?

137. Dr A. Schauer
Ipilimumab-induced Stevens Johnson Syndrome

138. Dr A. Schauer
Stretching scleromyxoedema treatment with IVIG

139. Mr A. Scott
A tattoo pigment reaction in a patient with metastatic melanoma treated with dabrafenib and trametinib

140. Dr J-A. See
High patient satisfaction with daylight-activated methyl aminolevulinate cream in the treatment of multiple actinic keratoses: A non-interventional study in Australia

141. Dr E. Shao
Botox and axillary hyperhidrosis: A retrospective study at a dermatology centre

142. Dr E. Shao
Erythema dyschromicum perstans and the betel nut

143. Dr E. Shao
Lepromatous leprosy: Case based clinico-histologic discussion

144. Dr E. Shao
Pachydermoperiostosis: A rare case study

145. Dr E. Shao
Panniculitis secondary to vancomycin

146. Dr E. Shao
Tattoo reactions: The experience of a dermatology centre offering tattoo removal services

147. Dr S. Sharma
Schnitzler syndrome: A rare cause of chronic recalcitrant urticaria

148. Mr J. Shen
Management of cutaneous adverse events associated with daclizumab treatment in multiple sclerosis patients

149. Ms E. Sideris
Patients’ sun practices, perceptions of skin cancer and their risk of skin cancer in rural Australia

150. Miss E. Sim
Fish tank granuloma in Chinese restaurant chefs in Victoria – an occupational hazard

151. Prof. R. Sinclair
Secukinumab provides faster, more sustained relief from psoriasis-related pain, itching and scaling than ustekinumab in subjects with moderate-to-severe plaque psoriasis

152. Dr A. Smith
Global dermatology - a trainee’s perspective

153. Dr S. Smithson
Consensus statement for the treatment of infantile haemangiomas with propranolol

154. Dr S. Smithson
The use of IVig for refractory bullous pemphigoid secondary to pembrolizumab: A case report

155. Dr S. Smithson
The use of mycophenolate mofetil to treat mid dermal elastolysis: A case report

156. Dr V. Snaidr
Pigmented epithelioid melanocytoma: Case report and update on the nomenclature of paediatric melanocytic tumours

157. Dr P. Sobarun
A rare acral lesion with parallel-ridge pattern on dermoscopy

158. Dr F. Spada
Is there a problem with parabens?

159. Dr F. Spada
Providing intense moisturisation for extremely dry skin

160. Dr L. Spelman
Secukinumab 300mgs is more efficacious than ustekinumab 90mgs: Analysis of patients with body weights over 100kg from the CLEAR study

161. Dr P. Star
Immunotherapy-induced pustular psoriasis in a patient with metastatic melanoma

162. Dr P. Stevenson
Multiple pilomatrixomas in a paediatric patient leading to a diagnosis of familial adenomatous polyposis

163. Dr P. Stevenson
Obtaining patients’ informed consent for clinical photographs: An audit of dermatology registrars’ practices at a tertiary hospital

164. Dr P. Stevenson
Treating severe plaque psoriasis in a paediatric patient with etanercept

165. Dr T. Stewart
A cross-sectional study of psychological stress and skin symptoms in Australian university students

166. Ms J. Stone
Comparison between parent versus clinician assessment of disease severity in childhood atopic dermatitis

167. Dr J. Sullivan
Secukinumab in pregnancy: Outcomes from the global safety database

168. Dr J. Sullivan
Secukinumab shows significant efficacy in nail psoriasis: Week 32 results from the TRANSFIGURE study

169. Dr A. Swarbrick
Cutaneous amyloidosis: Several illustrative cases

170. Dr A. Swarbrick
Toxic shock syndrome: Illustrating the importance of history and examination

171. Dr J-M. Tan
The prevalence of BRAF and NRAS in dermoscopic subtypes of acquired naevi

172. Dr Y. Tanaka
Cytocidal effect of water-filtered broad-spectrum near-infrared on cancer cells

173. Dr Y. Tanaka
The necessity of solar near-infrared protection shown through gene expression changes

174. Dr Y. Tanaka
Type I collagen production stimulation of water-filtered near-infrared shown through gene expression changes in a 3-dimensional human epidermal tissue model

175. Dr C. Tancharoen
An audit of inpatient dermatology admissions: Management of hyperglycaemia in oral glucocorticoid use
176. Dr S. Taylor
Efficacy and safety of topical dapsone gel 7.5% for treatment of acne vulgaris by fitzpatrick skin type

177. Dr C. Thomas
Non-melanoma skin cancer and quality of life in an Australian population

178. Dr C. Thomas
Strongyloides hyperinfection syndrome complicating corticosteroid therapy for pemphigus vulgaris

179. Dr S. Thomas
Involvement of selective melanocytic lesions in a 79-year-old male with metastatic melanoma on immunotherapy

180. Dr J. Tiing
An audit of pigmentation disorders due to infection seen at a private dermatology clinic in Western Australia

181. Dr J. Tiing
Epidermodysplasia verruciformis resembling pityriasis versicolor

182. Dr L. Timoney
A case of angiolymphoid hyperplasia with eosinophilia.

183. Dr L. Timoney
A rare case of primary rhabdoid malignant melanoma

184. Dr L. Timoney
Amelanotic lentigo maligna melanoma: Beware the wolf in sheep’s clothing

185. Dr L. Timoney
Myxoid dermatofibrosarcoma protuberans with fibrosarcomatous features

186. Dr R. Toholka
Erythema induratum, a classic case of a tuberculid reaction

187. Dr R. Toholka
Primary osteoma cutis

188. Dr E. Tong
Perils and pearls of purchasing sun protection on the internet

189. Dr M.C. Tran
Flagellate erythema: Review of causes, with dramatic case presentation in young female with dermatomyositis

190. Dr N. Valecha
Non-cultured melanocyte transplantation for treatment of stable leucoderma: Experiences of an Australian centre

191. Prof. G. Varigos
Essential for next 50 years dermatology clinical research registries at the bedside BIOGRID

192. Dr D. Vekic
SAPHO syndrome associated with hidradenitis suppurativa and pyoderma gangrenosum successfully treated with adalimumab and methotrexate

193. Dr D. Vekic
The expanding spectrum of autoimmune inflammatory syndromes related to hidradenitis suppurativa

194. Dr M. Vu
Brooke-spiegler syndrome: The impact of a rare disease

195. Dr M. Vu
Hypertrophic lichenoid reactions secondary to anti-PD-1 therapy

196. Dr M. Vu
Lichen planus following influenza immunisation

197. Dr M. Vu
Oral tofacitinib - a promising treatment in atopic dermatitis, alopecia areata and vitiligo

198. Dr T. Wain
Methotrexate in primary cutaneous t-cell lymphoma

199. Mr C. Wang
Acute localised exanthematous pustulosis secondary to pembrolizumab

200. Dr E. Wei
An annular purpuric eruption secondary to a lymphocytic vasculitis with mixed features of livedoid vasculitis and lymphocytic thrombophilic arteritis

201. Dr E. Wei
Australian dermatology trainee opinions on skin of colour education: Does it reflect the changing demographics of our population?

202. Dr J. Witherspoon
The management of dysplastic naevi: A survey of the fellows of The Australasian College of Dermatologists

203. Dr G.N. Wong
Case report: Secondary syphilis masquerading as tinea corporis

204. Dr V. Wong
Congenital erosive and vesicular dermatitis with reticulated supple scarring: A report of two new cases

205. Dr V. Wong
Narrowband ultraviolet B phototherapy in recalcitrant vulval psoriasis: A local treatment protocol and pilot study

206. Dr A. Wu
Proportion of melanoma excisions performed by different specialties in Australia

207. Dr C. Wyatt
Nodules in the newborn- 3 cases of congenital self-healing histiocytosis

208. Dr J. Xu
Melanomas in prepubescent children versus pubescent children in the Western Australian melanoma advisory service

209. Dr J. Xu
Paediatric melanomas: Western Australian melanoma advisory service experience

210. Dr A. Yang
DRESS induced by a weight loss protein shake - the misfortune of good intentions

211. Dr X. Yang
Intertriginous planar xanthoma secondary to dyslipidaemia in an infant

212. Dr F. Yap
A rare case of lues maligna with ocular involvement after immune reconstitution syndrome

213. Dr F. Yap
Capecitabine exacerbates psoriasis in colon cancer patients. A case report

214. Dr F. Yap
Erythema nodosum leprosum (ENL) with sub-acute mono-neuritis multiplex: A rare presentation and challenging disease to manage

215. Dr F. Yap
Perianal pseudoverrucous papules and nodules in hirschsprung’s disease: Rapid resolution with oral loperamide

216. Dr A. Yazdabadi
Artificial intelligence, predicting outcomes in photodynamic therapy

217. Prof. G. Yosipovitch
Validation of the peak pruritus numerical rating scale: Results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis

218. Dr C. Zhao
Anti-programmed cell death 1’s effects on cutaneous squamous cell carcinoma in patients with metastatic melanoma

219. Dr C. Zhao
Melanocytic lesion evolution patterns with targeted therapies and immunotherapies for advanced metastatic melanoma
AIMING FOR CLEAR TOUCHABLE SKIN.†1–8†

†Up to 41% of patients achieved PASI 100 at Week 12 in UNCOVER phase III trials; 58% of Week 12 responders (sPGA 0/1; pooled analysis of UNCOVER-1 and UNCOVER-2) maintained or achieved PASI 100 by Week 60; improvement at Week 12 vs baseline in areas associated with touch avoidance.1–8

AT WEEK 12
(UNCOVER-2
phase III trial):

90% OF PATIENTS
ACHIEVED
PASI 751,2

71% OF PATIENTS
ACHIEVED
PASI 901,2

41% OF PATIENTS
ACHIEVED
PASI 1001,2

PBS INFORMATION: Authority required. For the treatment of severe chronic plaque psoriasis. Refer to PBS Schedule for full Authority information.
FLOOR PLAN OF THE TRADE EXHIBITION AREA

HALL 1 FLOOR PLAN
## Looks Can Be Deceiving

In Atopic Dermatitis

To find out more please visit us at the Sanofi Genzyme stand


<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>AbbVie</td>
<td>81-86</td>
</tr>
<tr>
<td>Advanced Cosmeceuticals</td>
<td>93-95</td>
</tr>
<tr>
<td>Allergan</td>
<td>41-44</td>
</tr>
<tr>
<td>AllergEnd and Orbis Australasia</td>
<td>89</td>
</tr>
<tr>
<td>Aspen Pharmcare</td>
<td>13</td>
</tr>
<tr>
<td>Aussie Medi Tech</td>
<td>110</td>
</tr>
<tr>
<td>Australasian Blistering Diseases Foundation</td>
<td>22</td>
</tr>
<tr>
<td>Australasian College of Dermatologists</td>
<td>111-114</td>
</tr>
<tr>
<td>Australia Alopecia Areata Foundation (AAAF)</td>
<td>117</td>
</tr>
<tr>
<td>Australia and New Zealand Melanoma Trials Group</td>
<td>19</td>
</tr>
<tr>
<td>Australian Dermatology Equipment</td>
<td>102</td>
</tr>
<tr>
<td>Australian Gorlin Syndrome Support Group</td>
<td>118</td>
</tr>
<tr>
<td>Australian Ultra Violet Services</td>
<td>23</td>
</tr>
<tr>
<td>Avita Medical</td>
<td>96</td>
</tr>
<tr>
<td>Bayer Australia</td>
<td>39</td>
</tr>
<tr>
<td>BODERMA (CDF)</td>
<td>88</td>
</tr>
<tr>
<td>Bio-Oil</td>
<td>12</td>
</tr>
<tr>
<td>BOQ Specialist</td>
<td>14</td>
</tr>
<tr>
<td>BrightSkin Australia</td>
<td>94</td>
</tr>
<tr>
<td>Celgene</td>
<td>61-64</td>
</tr>
<tr>
<td>COMPOUNDED Pty Ltd</td>
<td>92</td>
</tr>
<tr>
<td>Critical Group</td>
<td>26</td>
</tr>
<tr>
<td>Cryomed Aesthetics</td>
<td>99</td>
</tr>
<tr>
<td>CustomMed Compounding Pharmacy</td>
<td>47</td>
</tr>
<tr>
<td>Cutera Australia</td>
<td>80</td>
</tr>
<tr>
<td>Cynosure</td>
<td>40</td>
</tr>
<tr>
<td>DEBRA Australia</td>
<td>116</td>
</tr>
<tr>
<td>Dermocosmetica</td>
<td>87</td>
</tr>
<tr>
<td>Dorevitch Pathology</td>
<td>45</td>
</tr>
<tr>
<td>Douglass Hanly Moir Pathology</td>
<td>121</td>
</tr>
<tr>
<td>Eczema Association of Australasia Inc</td>
<td>119</td>
</tr>
<tr>
<td>Ego Pharmaceuticals</td>
<td>103-106</td>
</tr>
<tr>
<td>Eli Lilly Australia</td>
<td>53-56</td>
</tr>
<tr>
<td>EndyMed Medical</td>
<td>15</td>
</tr>
<tr>
<td>Expanscience Laboratories - Mustela</td>
<td>107</td>
</tr>
<tr>
<td>Firstcheck</td>
<td>28</td>
</tr>
<tr>
<td>Galderma Australia</td>
<td>71-76</td>
</tr>
<tr>
<td>Genie Solutions</td>
<td>9</td>
</tr>
<tr>
<td>GlaxoSmithKline Australia (GSK)</td>
<td>77-79</td>
</tr>
<tr>
<td>Hands to Hold Ltd</td>
<td>115</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>COMPANY</th>
<th>STAND NUMBER</th>
</tr>
</thead>
<tbody>
<tr>
<td>HEINE Australia</td>
<td>1-2</td>
</tr>
<tr>
<td>High Tech Laser Australia</td>
<td>33</td>
</tr>
<tr>
<td>Ionia Medical</td>
<td>91</td>
</tr>
<tr>
<td>Janssen-Cilag</td>
<td>65-70</td>
</tr>
<tr>
<td>Johnson &amp; Johnson</td>
<td>10-11</td>
</tr>
<tr>
<td>Key Pharmaceuticals</td>
<td>97</td>
</tr>
<tr>
<td>K-Laser Australia</td>
<td>109</td>
</tr>
<tr>
<td>KOSmedical</td>
<td>109</td>
</tr>
<tr>
<td>Kossard Dermatopathologists</td>
<td>46</td>
</tr>
<tr>
<td>La Roche-Posay (LOREAL)</td>
<td>58 &amp; 60</td>
</tr>
<tr>
<td>LEO Pharma</td>
<td>5-8</td>
</tr>
<tr>
<td>Lumenis Australia</td>
<td>35-36</td>
</tr>
<tr>
<td>Cryomed</td>
<td>99</td>
</tr>
<tr>
<td>CustomMed Compounding Pharmacy</td>
<td>47</td>
</tr>
<tr>
<td>Cutera Australia</td>
<td>80</td>
</tr>
<tr>
<td>Cynosure</td>
<td>40</td>
</tr>
<tr>
<td>Macquarie Medical Systems</td>
<td>78</td>
</tr>
<tr>
<td>Marne Medical</td>
<td>29</td>
</tr>
<tr>
<td>Medifit Design &amp; Construct</td>
<td>4</td>
</tr>
<tr>
<td>Menarini Australia</td>
<td>32</td>
</tr>
<tr>
<td>Merz Australia</td>
<td>24-25</td>
</tr>
<tr>
<td>MSD</td>
<td>27</td>
</tr>
<tr>
<td>Mylan</td>
<td>98</td>
</tr>
<tr>
<td>NeoStrata</td>
<td>16</td>
</tr>
<tr>
<td>Nevus Support Australia Inc</td>
<td>120</td>
</tr>
<tr>
<td>Nice Pak Products</td>
<td>90</td>
</tr>
<tr>
<td>Novartis Pharmaceuticals</td>
<td>49-52</td>
</tr>
<tr>
<td>Oroderm Pharmaceuticals</td>
<td>34</td>
</tr>
<tr>
<td>Pierre Fabre (Avène)</td>
<td>37-38</td>
</tr>
<tr>
<td>Propaïra</td>
<td>30</td>
</tr>
<tr>
<td>Psoriasis Australia Inc</td>
<td>21</td>
</tr>
<tr>
<td>Sanofi Genzyme</td>
<td>57-59</td>
</tr>
<tr>
<td>Scanmedics (Paragon Care)</td>
<td>48</td>
</tr>
<tr>
<td>Skin &amp; Cancer Foundation Inc</td>
<td>18</td>
</tr>
<tr>
<td>Sun Pharma</td>
<td>100-101</td>
</tr>
<tr>
<td>Syneron Candela</td>
<td>31</td>
</tr>
<tr>
<td>The Australasian College of Dermatologists</td>
<td>111-114</td>
</tr>
<tr>
<td>The Skin Hospital and Skin &amp; Cancer Foundation Australia</td>
<td>17</td>
</tr>
<tr>
<td>Vitiligo Association of Australia (VAA)</td>
<td>20</td>
</tr>
<tr>
<td>Vorotek</td>
<td>108</td>
</tr>
</tbody>
</table>
ACKNOWLEDGEMENTS

The Australasian College of Dermatologists kindly acknowledges the generous support of the following sponsors in assisting with the Annual Scientific Meeting:

PLATINUM SPONSORS

NOVARTIS

Lilly

GOLD SPONSORS

Celgene

Janssen Immunology

SILVER SPONSORS

SANOFI GENZYME

GALDERMA

OTHER SPONSORS

AAAFA

WILEY